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Hepatitis C virus (HCV) is a public health crisis, affecting over 170 million people by 
2011. Conventional treatment, interferon alpha with ribavirin, can often be ineffective 
and may lead to severe side effects, and this lack of effective treatment poses 
significant challenges to patients, healthcare providers, and public health officials. As 
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a result, our team investigated the therapeutic potential of medicinal plant extracts 
from Phyllanthus niruri as an alternative treatment for HCV.  Molecular barcoding of 
chloroplast genes rbcl and matk was used to document the genetic identity of our 
plants.  Phytochemicals were then extracted from dried plant material to isolate 
potential active compounds.  We applied the extraction products to HCV-infected cell 
lines, specifically Huh7.5 liver cancer cells with J6JFH virus, to determine their 
effects on viral load and cell toxicity.  Our extracts significantly decrease the number 
of viral copies per cell with no significant toxicity.  Viral load suppression was 
strongest 24 hours after treatment.  This effect either declined (extracts 3 and 4) or 
was sustained (extracts 1 and 2) over time.  Extract 4 at 1 g/ml at 24 hours and 5 at 
10 g/ml at 96 hours reached near 100% suppression, demonstrating significant 
potent effect comparable to interferon-alpha, but the effect of Extract 4 is not 
sustained.  It also demonstrates different extracts may exhibit different kinetics, 
suggesting different mechanisms of action.  Overall, our study serves as a building 
block to develop novel treatments and contributes to the discovery of alternative drug 
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Chapter 1: Introduction 
 
Section 1: 1.1.0 Team ANTIDOTE 
The Gemstone Program at the University of Maryland, College Park is a 
living-learning program that enables teams of undergraduate students to engage in 
interdisciplinary research under the guidance of faculty mentors.  Team ANTIDOTE 
comprises of fourteen undergraduate students in the Gemstone program that 
conducted research under the guidance of Dr. Andrea Ottesen of the College of 
Agriculture & Natural Resources at the University of Maryland, College Park, and the 
Food and Drug Administration (FDA), and Dr. Shyam Kottilil, of the National 
Institutes of Allergies and Infectious Diseases (NIAID) at the National Institutes of 
Health (NIH).   
The use of natural products to treat ailments has been a common practice 
throughout history in many regions of the world. While herbal remedies are often 
trusted because they are considered to be time-tested, their potential has also captured 
the interest of scientists involved in drug discovery and development. Because natural 
products are so diverse in nature, research in this area permits “the identification of 
lead molecules of greater interest for the development of new therapeutic agents, as 
well as biochemical and molecular tools needed to clarify complex cellular and 
molecular mechanisms of action involved in most physiological and pathological 
processes” (Calixto, Santos, Filho, & Yunes, 1998). One subset of herbal medicine 
research involves the study of “edible plants containing antioxidants and health-
promoting phytochemicals” (Sabir & Rocha, 2008). Polyphenolic compounds found 
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in the vegetables, fruits, and teas of such plants have been correlated with the low risk 
of chronic diseases such as heart disease, stroke, arthritis, diabetes and cancer (Sabir 
& Rocha, 2008). The members of our team are amongst those who are greatly 
intrigued by this prospect, and it was with this curiosity and concern that we formed 
Team ANTIDOTE. With our team, we planned to respond to the need for the 
development of alternative medicinal treatments for the hepatitis C Virus (HCV). 
The project idea began after one team member spent a summer at the National 
Institutes of Health, where she heard about patients with HIV/hepatitis C co-infection.  
When she later traveled abroad to Peru to study medicinal plants of the Amazon 
rainforest, she encountered phyllanthus niruri, a plant that seemed tremendously 
understudied but held great therapeutic potential in the liver and against HIV 
(Chirdchupunseree & Pramyothin, 2010) (Qian-Cutrone, 1996).  Having also learned 
that an infectious model of the hepatitis C virus cell culture system had only been 
developed in 2005 (Duverlie & Wychowski, 2007), just three and a half years prior to 
start of the project, and finding that little research had been done specifically with this 
plant on hepatitis C, she thought that combining phyllanthus and HCV would be a 
great opportunity to contribute new knowledge.  The project idea was proposed 
through the Gemstone Program and Team ANTIDOTE was formed in spring of 2009. 
 
 
Section 2: 1.2.0 Status of HCV treatment 
Hepatitis C, an infectious liver disease, affects 170 million people worldwide, 
with almost 4 million cases in the United States alone (World Health Organization, 
2011).  Most people with hepatitis C, caused by the hepatitis C virus (HCV), have no 
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symptoms, or develop symptoms that eventually get better.  Those who do develop 
symptoms often suffer from fatigue, jaundice, abdominal pain, and vomiting 
(NIAID).  However, most people, 75%-85%, will also develop chronic hepatitis C. 
Chronic hepatitis C is a long-term illness that can lead to serious liver complications, 
including cirrhosis and liver cancer (CDC, 2009).   In fact, hepatitis C is the leading 
cause of cirrhosis and liver cancer in the United States and the most common reason 
for liver transplantation, with 8,000-10,000 people dying from hepatitis C 
complications each year (CDC, 2009). 
Currently, there is no vaccine available for hepatitis C, and the most common 
medication, pegylated interferon alpha and ribavirin, is often ineffective and induce 
very serious side effects.   For patients treated with both pegylated interferon alpha 
and ribavirin, only 40% are able to clear HCV from the blood (Brok, Gluud, & 
Gluud, 2010).  Typically, pegylated interferon alpha and ribavirin are given 
simultaneously for 24-48 weeks (Dugdale, Longstreth & Zieve, 2010).  Interferon, 
given as a shot, is a protein that the body produces to fight infections.  Pegylated 
interferon injections are given once a week.  Ribavirin is a capsule that has to be 
taken twice a day.  However, ribavirin by itself is ineffective and has to be taken 
along with interferon injections (Dugdale, Longstreth & Zieve, 2010).   
Recently, the FDA approved protease inhibitors that can be given along with 
interferon and ribavirin to help improve effectiveness (FDA, 2011).  Two new 
protease inhibitors, boceprevir and telaprevir, have been clinically shown to improve 
the cure rate from 50% to 70-80% (McQueen, 2011).  However, the approval of these 
drugs does not eliminate the use of interferon, and these drugs are now prescribed in 
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combination with interferon.  This means that the side effects of interferon can still 
persist in conventional treatment (Canavan, 2012).  
 
Section 3: 1.3.0 Problems with HCV treatment 
The need for research in remedial alternatives against HCV stems primarily 
from the multitude of side effects associated with the current treatment of the virus. 
As aforementioned, pegylated interferon alpha with ribavirin is used to increase the 
body’s ability to fight off infection and to specifically combat the virus ("Hepatitis C 
treatment:," 2011). However, the side effects of these drugs include fatigue, 
gastrointestinal disturbances, influenza-like symptoms, and hematologic 
abnormalities (Fried, 2002). While these are the more commonly experienced side 
effects, some patients have experienced more serious effects such as retinopathy, 
retinal hemorrhage, visual loss, tinnitus, hearing loss, cardiac arrhythmias, and 
congestive heart failure (Fried, 2002). These side effects have caused patients to 
resort to lower drug dosages, which compromises the activity of drug against the 
virus. It has even been the case that patients have had to terminate treatment 
altogether in order to prevent the damage caused by the more serious side effects 
(Fried, 2002). Some side effects have been deemed transient during the patient’s 
therapy, while others last throughout the entirety of the patient’s treatment ("Hepatitis 
C treatment:," 2011). The lack of an alternative treatment has left these potentially 
detrimental side effects and discomforts to persist in many HCV patients – and 
unfortunately, the side-effect profile of standard treatment has remained “largely 
unchanged” since its initial release in the late 1990s and early 2000s (Russo & Fried, 
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2003). The search for alternative therapy, therefore, such as the exploration of herbal 
remedies, is necessary in order to see if there is another effective method against 
HCV that does not have to involve such uncomfortable -- if not detrimental -- side 
effects. 
 
Section 4: 1.4.0 Problems with herbal remedies 
In recent decades, the recognition of alternative medicine has become 
increasing popular in North America. Since the adverse effects of conventional drug 
therapies are well documented, people have started to use natural remedies as 
potentially effective and less toxic alternatives to pharmaceutical agents (Elvin-
Lewis, 2000). Herbal medicine can be separated into four major types: Indigenous 
herbalism, Asian medicinal systems, European herbalism, and Neo-Western 
herbalism (Elvin-Lewis, 2000), and with this wide range of sources, there are 
numerous regulatory challenges to alternative medicine. In the United States, 
regulation of herbal products only began around 1994 when the Dietary Supplement 
Health and Education Act (DSHEA) was enacted. Under this act, herbal remedies 
became exempt from strict FDA regulations as long as the labeling of these products 
did not contain medical claims (Elvin-Lewis, 2000). However, these broad guidelines 
lack proper evaluation of herbal remedies in terms of safety and efficacy. The lack of 
regulation means that a variety of factors can cause herb toxicity including 
misidentification of plants, contamination, incorrect handling of the plant, and 
improper storage (Whiting, Clouston, & Kerlin, 2002). In addition, the use of herbal 
medication in conjunction with pharmaceutical drugs can cause a variety of adverse 
side effects due to the antagonism of the drug by herbal compounds. For instance, 
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cinnamon with tetracycline can cause hallucinations and valerian with anti-histamines 
can cause sedative effects (Elvin-Lewis, 2000).  
For chronic diseases without effective treatments such as hepatitis C, the use 
of alternative medicine is becoming more prevalent. In one particular study, up to 46 
percent of patients attending liver disease clinics admitted to using some form of 
alternative medicine at least once in the month prior (White, Hirsch, Patel, Adams, & 
Peltekian, 2007). The high percentage of HCV patients who use alternative therapies 
is not surprising given that they are perceived to be safe and without side effects. 
However, this overconfidence in the safety of herbal therapies can be dangerous since 
the improper use, preparation, and quality of herbal therapies can have significant 
harmful effects. A universal regulation system with documented efficacy would be 
helpful in evaluating herbal remedies and preventing improper use.  
 
Section 5: 1.5.0 Objectives 
To address the need for additional research in the area of herbal medicine and 
alternative treatments for HCV, the primary goal of our research project was to 
examine the manner in which extracts of P. niruri affect the cell viability and viral 
load in cells infected with HCV. The research questions guiding this project were: 
 Are there any biologically active fractions in P. niruri against hepatitis C virus 
and how do they affect viral load and cell viability? 
 What is the effect of extracts from P. niruri when combined with and 
compared to medicines used in conventional treatment of HCV, specifically 
standard interferon alpha for HCV? 
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In order to organize and facilitate the answering of these overarching 
questions, we divided our primary research objective into three specific objectives: 
1. To extract and identify the active compounds from P. niruri that were said to 
have therapeutic potential against HCV. 
2. To genetically barcode P. niruri plant samples grown and used in chemical 
extractions to ensure that all plants used were from one species and to 
establish a clarified taxonomic identity for P. niruri. 
3. To quantitatively and qualitatively determine the efficacy of active P. niruri 
extracts on HCV-infected cell lines via cell studies which focus on measuring 
cell viability and viral load. 
 
Section 6: 1.6.0 Outline of Study 
P. niruri seeds were purchased through online vendors and cultivated with 
assistance from U.S Botanical Garden and sustained by the University of Maryland 
Greenhouse. 
Objective 1 was accomplished through a methanol extraction and partitioning 
of the different extract layers. These fractions were later analyzed through HPLC to 
compare the phytochemical content between fractions of different purity. 
Objective 2 was accomplished by tracking the plants used in the chemical 
extractions to determine whether the samples used were genetically identical. DNA 
barcoding was done by amplifying and sequencing target regions of the P. niruri 
genome in order to construct phylogenetic trees of all plants used. 
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Objective 3 was accomplished by analyzing the efficacy of P. niruri extracts 
on Huh7.5 liver cancer cell line infected with a strain of the HCV virus. Cell viability 
and viral load was quantified after treating with the cell line with the various fractions 
of extract. This was done by employing the MTS assay and quantitative real-time 
PCR. The results of these experiments allowed for a correlation to be made between 
the use of P. niruri as a form of treatment and HCV. 
 
Section: 1.7.0 Hypothesis 
We hypothesize that individual P. niruri plants used during experimentation 
are genetically identical.  Furthermore, we hypothesized that the extracted compounds 
from P. niruri will have antiviral effects on cell cultures for hepatitis C as seen 













Chapter 2: Literature Review 
 
Section 1: 2.1.0 Phyllanthus 
Phyllanthus (Euphorbiaceae) is a broad genus, comprising between 550-750 
species and 10 to 11 subgenera, with roughly 200 species growing in tropical and 
temperate regions of the Americas and the Caribbean (Calixto, Santos, Filho, & 
Yunes, 1998).  Species of Phyllanthus are found growing in many tropical regions 
such as India, Africa, the West Indies, and South America. It has a geographically 
wide spread distribution which makes it difficult to find its point of origin.   
Plants of this genus were first recorded by Swedish botanist and taxonomic 
pioneer, Carl Linneaus, in 1737 (Linneaus, 1738).  However, prior to its first 
taxonomic record, phyllanthus had a long tradition in local medicinal therapies 
(Webster, 1957).  Specifically, members of this genus had already been used for 
thousands of years in the folkloric medicine of Brazil, India, and China.  Known in 
Brazil as “quebra pedra,” or “stone breaker,” Phyllanthus was often used to treat a 
wide range of ailments, particularly those affecting the kidneys and urinary bladder 
(Calixto, Santos, Filho, & Yunes, 1998). “Quebra pedra” is a general name that 
encompasses a handful of different Phyllanthus species, especially, P. niruri, P. 
uririnaria, P. amarus, P. tenellus, and P. caroliniensis (Calixto, Santos, Filho, & 
Yunes, 1998).   
This study focuses on one particular species in the Phyllanthus genus, P. 
niruri, and its potential for use in the treatment of hepatitis C.  In Brazilian folk 
medicine, P. niruri is among the most commonly used plant that is classified as 
“quebra pedra” due to its widespread availability in Brazilian municipalities (Calixto, 
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Santos, Filho, & Yunes, 1998).  In more recent years, however, P. niruri has garnered 
the attention of the international medical community due to its inhibitory effects 
against hepatitis B, and most recently, antiviral activity against the human 
immunodeficiency virus (HIV) and hepatitis C (Qian-Cutrone et al., 1996). 
 
Section 2: 2.2.0 P. Niruri 
P. niruri is a small, erect annual herb that grows 30 to 50 cm (1 to 2 feet) in 
height (Vieira, 1999, Wiart 2006a).  It has green oblong, oblate, alternate leaves up to 
9 millimeters in length and two to five millimeters wide (Wiart, 2006a).  The name 
Phyllanthus means “leaf and flower,” because the fruit and flower of Phyllanthus 
species seem to become one with the leaf (Patel, Tripathi, Sharm, Cauhan, & Dixit, 
2011).  The petiole is indistinct, and the base and the apex are around.  The male 
flowers are very small, comprised of three stamens and often found in groups of two 
to three in the lowest axils.  The female flowers are much larger, in higher axils with 
oval sepals. The fruits are tiny, smooth, three-lobed capsules. The seeds are very 
small and longitudinally ribbed (Wiart, 2006b).  See Appendix M for a diagram. 
P. niruri is thought to be mainly localized to the tropical regions in the 






Subsection 1: 2.2.1 Taxonomy 
The anatomical features of members of the Phyllanthus genus have been 
described by various sources. Related sister species are very similar in appearance 
and are thus easily mistaken for each other. Two common Phyllanthus species are 
described below. 
P. amarus stands at roughly 1.5 feet tall and has smooth, reddish stems that 
are extensively branched. Their simple leaves have stipules and are light green in 
color, alternately attached to a long skinny stem. The petiole, which is the stalk that 
attaches the leaf to the stem, is not prominent in the P. amarus species. The plant is 
monoecious; having both male and female reproductive parts on the same specimen. 
Male flowers of this species have three stamens. They are small and clustered at the 
lower portion of the plant while the female flowers are large, non-clustered, and 
located in the upper portion of the plant. Fruits are spherical and smooth containing 
three lobes with very small seeds (Wiart, 2006a).  
P. niruri Linn., stands roughly 2 feet tall. Its stem is smooth and does not have 
a bark layer. Leaves, similar to that of P. amarus, are small, alternating, and oblong in 
shape. Leaves contain ranunculaceous stomates, similar to that of the buttercup 
family. Some vascular tissue is visible under the palisade cell layer. Leaves are 
covered with a thin cuticle over the epidermis (Kapoor, 2001). This monoecious 
species has small flowers that grow in pairs parallel to the position of leaves on the 
stem. Fruits are capsulated, small, and ridged. Further anatomical features are 
gathered through a cross section of the stem. The outer epidermis layer is made up of 
box-shaped cells. The middle cortex layer is thick and the inner pith can be 
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distinctively identified. Vascular tissue, xylem and phloem, are arranged in rings.  P. 
niruri has been deemed to be synonymous to species previously misclassified as P. 
fraternus Web. (Kapoor, 2001). 
 
Subsection 2: 2.2.2 Taxonomic Confusion 
P. niruri is taxonomically confused with other species classified as “quebra 
pedra,” especially P. amarus and P. urinaria.  This confusion stems from its original 
classification by Carl Linnaeus, who erroneously classified a number of closely 
related and taxonomically similar species as P. niruri, leading to further 
misidentification and misclassifications by subsequent scientists (Patel, Tripathi, 
Sharm, Chauhan, & Dixit, 2011).  To complicate matters, the Brazilian name “quebra 
pedra” does not identify a single species, but instead refers to a handful of similar 
species.  Likewise, in India, the common name of this class of herb applies for both P. 
niruri and P. urinaria, even though P. urinaria usually appears to be somewhat 
visually different (Patel, Tripathi, Sharm, Chauhan, & Dixit, 2011).  The original 
specimens of P. niruri first identified by Linnaeus in 1737 were collected in 
Barbados, and it remains unclear whether true specimens matching these originals 
have been observed outside of the Americas (Webster, 1957). In fact, the so-called P. 
niruri described in India has been reported to be a mixture of three distinct species: P. 
amarus, P. fraternus, and P. debilis (Mitra & Jain, 1985). 
The lack of consensus about the identity of P. niruri has led to some 
confusion and disagreement among researchers studying this species.  This becomes 
especially problematic in the fabrication and regulation of herbal medicines, where 
the authenticity of the plants must be verified in order to ensure the quality and safety 
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of the herbal remedy in question (Martins, Pereira-Filho, & Cass, 2011).  For 
instance, the Brazilian Pharmacopeia only recognizes two Phyllanthus species: P. 
niruri and P. tenellus as being therapeutically active and safe for human consumption 
(Martins, Pereira-Filho, & Cass, 2011).  Due to the prevalence of co-habiting species 
of morphologically similar Phyllanthus, there is a high probability that local farmers 
or collectors create admixtures of several different species, especially since 
taxonomists are rarely consulted during the collection process (Srirama et al., 2010). 
Since different species within the Phyllanthus genus have differing 
composition percentages of bioactive compounds, different plants can elicit different 
degrees of biological activity once they are consumed (Lee, Jagannath, Wang, & 
Sekaran, 2011).  In some cases, the taxonomic similarity of Phyllanthus plants can 
cause the unintentional substitution of a plant that is not approved to be 
therapeutically active (Martins, Pereira-Filho, & Cass, 2011).  In a comparative study 
by Khatoon et al. in 2006, it was shown that three commonly mixed species of 
Phyllanthus contained significantly different phytochemistries.  P. amarus, P. 
fraternus, and P. maderaspatensis are all sold and used in India for the treatment of 
liver and kidney ailments, yet only one of them, P. amarus, contained the known 
hepatoprotective compounds, phyllanthin and hypophyllanthin.  Such admixtures 
could lead to a decreased efficacy of treatment or even toxic effects (Khatoon, Rai, 
Raway & Mehrotra, 2006).  Therefore, a major concern for phytomedicine is the 
creation of simple, cost-effective methods to assure the identity of raw plant material 
and the herbal medicines created from them.   
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Section 3: 2.3.0 Taxonomic identification and chromatographic fingerprinting 
Until the recent past, most plant samples were taxonomically identified 
according to the physical appearance -- such as the size, shape, and color -- of 
features such as the leaves, stem, flowers, and seed.   However, since this method 
relies heavily on the quality and age of the sample, it is often difficult to make these 
determinations based on physical appearances alone. ("What is dna," 2012) 
Chromatographic fingerprinting recently has emerged as a simple method of 
validating herbal samples and differentiating species. This method allows for 
validation and comparison between the complex phytochemical products of herbal 
extracts and plant-based medicine against a known or “standard” extract.  In the 
context of herbal medicines, it allows comparison on the chemical level between 
herbal batches supposed to contain a single plant species (Martins, Periera-Filho, & 
Cass, 2011). 
Brazilian scientists have attempted to combat these issues utilizing 
chromatographic fingerprinting as a technique for quick and accurate identification of 
P. niruri.  In 2009, Colombo et al. published a standard high performance liquid 
chromatography (HPLC) method for evaluating P. niruri samples obtained from 
commercial vendors. This was done through the identification of three major 
compounds present in both the leaves of the herb and commercial extracts: corilagin, 
rutin, and ethyl 3,4,5-trihydroxybenzoate. The first of these compounds, corilagin has 
been proposed as a phytochemical marker for P. niruri and was used to develop rapid 
and efficient HPLC conditions to assay for the presence of this chemical in the plant 
samples. Theoretically, this could be expanded to test the reliability and authenticity 
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of samples commonly sold on the market. This method is beneficial because it is 
quick and simple, requires little plant matter to perform HPLC analysis, and does not 
require the whole plant for physical taxonomical identification (Colombo, 2009). 
However, this method is not without limitations.  There is often a degree of 
chemical variation within a plant species since factors such as growing conditions 
may cause the relative concentrations of compounds between plant specimens to vary 
(Martins, Periera-Filho, & Cass, 2011). Such growing conditions include sunlight, 
temperature, water, location, and the availability of nutrients.  Thus, while it is 
possible to use chromatographic differences to discern between plant samples from 
different genera, it does not provide an ideal method for taxonomic speciation 
(Martins, Periera-Filho, & Cass, 2011). 
 
Section 4: 2.4.0 DNA Barcoding 
Due to the limitations of taxonomic and chromatographic methods of 
identification, biodiversity research has been trending towards DNA barcoding.  DNA 
barcoding uses short DNA sequences between 400 and 800 base pairs as “barcoding 
regions” that can be used to characterize and identify species, utilizing the fact that 
there is a degree of genetic variation between different species within the same genus 
(Kress, Wurdack, Zimmer, Weigt, & Janzen, 2005).  Barcoding regions must exhibit 
sufficient genetic divergence between species in order to be used as effective markers 
(Kress & Erickson, 2008b).  By cataloguing the barcoding regions of as many species 
as possible, an organization called the Consortium for the Barcode of Life aims to 
create a virtual database of species identifiers that can be publicly accessed to match 
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unknown specimens to known species (Kress, Wurdack, Zimmer, Weigt, & Janzen, 
2005). 
However, there has been difficulty in finding regions that meet the criteria 
necessary for a DNA barcode.  These requirements include high variation of DNA 
regions within species of the same genus, conserved barcode flanking regions that 
allow for the use of universal primers, and a relatively short length to facilitate DNA 
amplification (Kress & Erickson, 2008a). For animals, the most successful region has 
been a short sequence in the cytochrome c oxidase 1 (CO1) gene (Kress, Wurdack, 
Zimmer, Weigt, & Janzen, 2005). The CO1 region has already been used in a number 
of studies. For plants, however, the identification of a region has been more 
challenging due to the fact that the CO1 region evolves much more slowly in plants 
than in animals (Kress, Wurdack, Zimmer, Weigt, & Janzen, 2005).    
Despite these difficulties there has been some success in finding regions that 
show promise as possible DNA barcode loci for land plants.  Kress and colleagues in 
2005 and Kress and Erickson in 2007 both recommended the psbA-trnH spacer 
region and the rbcL gene as potential barcode loci.   A more recent paper by 
Hollingsworth et al. (2009) recommended a combination of rbcL and matK, two gene 
regions in the chloroplast, as the most effective DNA barcode for plants.  The matK 
chloroplast coding region has the advantage of having a rapid substitution rate 
compared to other regions.  When used in conjunction with another region such as 
psbA-trnH (a chloroplast spacer region), it was found that matK could distinguish 
between 90% of species tested (Hollingsworth, 2008).   
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Recently, there has been some success in species-level discrimination of 
Phyllanthus using DNA barcoding.  In a study by Srirama et al. (2010), psbA-trnH 
was used to effectively differentiate between sixteen species of Phyllanthus .  In their 
study, 95% of Phyllanthus specimens collected from vendors throughout southern 
India were identified as belonging to one of six Phyllanthus species (Srirama et al., 
2010).  Although the official barcoding regions for land plants was decided to be rbcL 
and matK, it is possible that the psbA-trnH region may prove to be a more effective 
region in the speciation of Phyllanthus plants.  At the very least, this region may be 
used to provide additional DNA evidence in the identification of plants when 
contrasted with using rbcL and matK alone. 
In November 2009, the Consortium for the Barcode of Life reported in Nature 
that it had chosen rbcL and matK as the approved DNA barcode (Hollingsworth et al., 
2009).  In accordance with the Consortium for the Barcode of Life’s decision, rbcL 
and matK were used to positively identify Phyllanthus specimens used in this study. 
 
Section 5: 2.5.0 Historical Perspectives: Traditional use in India/Brazil 
Plants belonging to the Phyllanthus genus have a long history of use in the 
folkloric medicine in countries such as Brazil and India.  Although scientific study of 
Phyllanthus genus is fairly recent, it has been used in traditional herbal remedies for 
over two thousand years due to its demonstrated therapeutic potential.  In Brazilian 
folkloric medicine, the Phyllanthus genus is commonly used to treat urinary 
infections and kidney stones (Calixto, Santos, Filho, Yunes, 1998).  In Indian 
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Ayurvedic medicine, the Phyllanthus genus is used to treat ailments involving the 
stomach, liver, kidney and spleen (Patel, Tripathi, Sharm, Chauhan, & Dixit, 2011).   
 
Subsection 1: 2.5.1 Traditional Use in Brazil 
The use of herbal medicines is commonplace in the localities of Brazil 
(Martins, Pereira-Filho, & Cass, 2011).  Brazilians typically have used P. niruri in 
order to prevent and cure urolithiasis, or kidney stones.  As a result of its positive 
effect on kidney stones, certain plants of the Phyllanthus genus have been given the 
common name “quebra-pedra,” which translates as “stone breaker” or “shatter stone” 
(Martins, Pereira-Filho, & Cass, 2011).  Phyllanthus leaves are typically steeped in 
water to make a tea that is then consumed orally (Cartaxo, Souza, & de Albuquerque, 
2010).   
Phyllanthus is one of the more popular herbal remedies on the market, and can 
be acquired in local markets, pharmacies, and herbal remedy stores.  It is typically 
sold as dried and chopped fragments of leaves, seeds, and stems (Martins, Pereira-
Filho, & Cass, 2011).  “Quebra pedra” is typically advertised to the locals as a 
treatment option for urolithiasis and other kidney and bladder afflictions.  
Unfortunately, the taxonomic similarity of several co-habiting plant species (of both 
Phyallnthus and other genuses) has led to confusion among suppliers and vendors.  
As a result, a handful of species of plants are being sold under the same name. One 
study collected 16 “quebra pedra” samples from 14 sellers in a street market in Porto 
Alegre, Rio Grander do Sul, Brazil.  Even though all samples claimed to be “quebra-
pedras,” there were seven different species of plant.  P. niruri was the only plant from 
the Phyllanthus genus of the seven species and the only plant proven to have 
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therapeutic potential.  Researchers found that after being dried and fragmented for 
selling, P. niruri and other Euphorbia products appeared to be more morphologically 




Subsection 2: 2.5.2 Ayurvedic Use of Phyllanthus in India 
In India, Phyllanthus is used to treat a wide range of ailments including 
migraines, jaundice, gonorrhea, syphilis, skin diseases, malaria, menstrual problems, 
diabetes, chronic dysentery, liver disease, anorexia, constipation, irritable bowel 
syndrome, and urinary tract infection (Patel, Tripathi, Sharm, Chauhan, & Dixit, 
2011).  Herbal remedies are typically prescribed by herbal doctors that follow an 
alternative system of medicine practiced in India, called Ayurved (Vijendra & Khatri, 
2010). 
The most common ways of preparing Phyllanthus is by boiling plant matter to 
make a tea that is consumed, or by creating a paste that is applied to the affected area 
of the skin (Patel, Tripathi, Sharm, Chauhan, & Dixit, 2011).  Sometimes, certain 
parts of the plant are used (such as leaves only or roots only), and other times, the 
whole plant may be used. For instance, in order to cure jaundice, the traditional 
remedies suggest grinding Phyllanthus leaves into a powder and creating a tea or 
creating fresh juice from the whole plant and ingesting it 3-4 times per day (Singh, 
Raghubanshi, & Singh, 2002).  Ayurvedic practitioners in India also use Phyllanthus 
to help support healthy liver function and to treat liver diseases, such as hepatitis, 
jaundice, and liver cancer (Unander, Bryan, Lance, & McMillan, 1993). 
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     Due to its widely-recognized therapeutic effects, Phyllanthus is commonly 
sold in markets in India.  In one study, morphological analysis was performed on 
samples from 25 different markets, and six different species were found even though 
they were all labeled as the same plant (Srirama et al., 2010).  Due to the taxonomic 
confusion between Phyllanthus species and its widespread usage in traditional Indian 
medicine, more stringent herbal market regulation is necessary. 
 
Subsection 3: 2.5.3 Regulation of Phytomedicines in India and Brazil 
The widespread use of herbal medicines, such as Phyllanthus, necessitates the 
creation of guidelines for safety.  The World Health Organization (WHO, 2000) has 
published guidelines to help regulate herbal medicine for national regulatory 
authorities, scientific organizations and manufacturers. WHO advocates 4 main steps 
for regulation: (1) assessment of quality; (2) assessment of safety; (3) assessment of 
efficacy and (4) intended use. Documentation of these parameters would allow for 
better regulation of the market for traditional herbal medicines.  Despite this 
suggestion, the regulation of Phyllanthus has remained minimal at best. 
In India, herbal drugs have been regulated since 1940 and are available both 
through prescription and over-the-counter.  All herbal drugs are regulated by the 
Department of Ayurveda, Yoga, & Naturopathy, Unani, Siddha, and Homeopathy 
(AYUSH), although herbal drugs are generally not required to provide evidence of 




Brazil, on the other hand, has a much stricter guideline for herbal medicine.  
Herbal medicines are considered drugs and therefore are required to show complete 
documentation of efficacy, safety, and quality control (Calixto, 2005).  Furthermore, 
for older medicinal herbs that are already registered, it is required to assess their 
safety for 5 years, and efficacy for 10 years. (Calixto, 2000) 
The Brazilian Pharmacopeia has approved and identified only P. niruri and P. 
tenellus as effective and safe for human consumption (Martins, Pereira-Filho, & Cass, 
2011).  However, it is incredibly difficult to control the chemical quality of herbal 
medicine because native medicinal plants are cultivated and collected from many 
different areas of the country.  Furthermore, different species of Phyllanthus plants 
share morphological features, causing confusion between therapeutically active plants 
and those that are not.  Since collectors rarely consult taxonomists or have access to 
advanced identification methods such as chromatographic fingerprinting or molecular 
barcoding, it is easy for misidentification of co-habiting Phyllanthus species to occur. 
(Martins, Pereira-Filho, & Cass, 2011). 
 
Section 6: 2.6.0 P. niruri and Liver 
Extracts of P. niruri have shown therapeutic potential against rising 
cholesterol levels in the liver and bloodstream.  A recent study showed that P. niruri 
could increase high density lipoprotein (HDL) levels by increasing the activity of an 
enzyme known as lecithin cholesterol acyltransferase (LCAT). The primary role of 
this enzyme is to synthesize HDL, which is commonly referred to as “good 
cholesterol.”  The study also showed that P. niruri was able to facilitate the rapid 
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catabolism of LDL (low-density lipoprotein, known as “bad cholesterol”) through 
LDL receptors in the hyperlipemic environment of cholesterol-fed rats (Khanna, 
Rizvi, & Chander, 2002).  This dual mechanism in which P. niruri alters cholesterol 
levels aptly applies to our project because HCV recently has been shown to have an 
affinity for the same receptors as low-density lipoproteins (LDL) (Khanna, Rizvi, & 
Chander, 2002).  Because of this result, scientists proposed that the LDL receptor is 
competitively inhibited by the HCV virus.  The rapid binding of beta-lipoproteins is 
stimulated by P. niruri treatment which, in turn, competitively inhibits the 
involvement of HCV antigens with the LDL receptors that the virus uses to propagate 
itself and cause damage to the liver. 
An important compound that has been isolated from plants of the Phyllanthus 
genus is a lignin called phyllanthin (Sharma).  One study investigated the effect of 
phyllanthin on ethanol-induced cytotoxicity.  In this study, rat hepatocytes were 
treated with ethanol, causing a decrease in cell viability because of membrane 
integrity impairment and oxidative damage.  Phyllanthin was subsequently tested on 
liver cells and researchers found that its hepatoprotective properties helped improve 
cell viability.  However, it was found that the whole extract (obtained from P. 
amarus) rather than phyllanthin alone, displayed a more rapid restoration of liver cell 
health and a greater increase in cell viability.  This suggests that there are other 
phytochemicals in the extract that contribute to the hepatoprotective activity of 
Phyllanthus species (Chirdchupunseree & Pramyothin, 2010).  
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Section 7: 2.7.0 Antiviral activity of Phyllanthus extracts 
P. niruri has demonstrated antiviral properties in both in vitro and in vivo 
studies.  Specific viruses that have been effectively treated include hepatitis B virus 
(HBV), hepatitis C virus (HCV), and woodchuck hepatitis virus (WBV) 
(Venkateswaran, Millman, & Blumberg, 1987). 
 
Subsection 1: 2.7.1 Phyllanthus and WBV and HBV 
In a landmark study by Venkateswaran, Millman, and Blumberg (1987),  the 
effects of an extract of P. niruri were examined on woodchuck hepatitis virus 
(WBV).  Since WBV and HBV have substantial cross-reactivity and significant 
homology of DNA, WBV can serve as a proxy for human hepatitis B virus 
(Venkateswaran, Millman, & Blumberg, 1987).  This study was conducted with the 
principal goal of determining if a plant extract such as P. niruri could inhibit 
endogenous DNA polymerase of HBV, which is necessary for the replication of the 
virus.  By inhibiting HBV DNA polymerase, the viral load of the cells could 
effectively be neutralized.  Venkateswaran, Millman, and Blumberg (1987) suggested 
that the extract had a positive effect via “prevention by delay”.   
This relationship between hepatocellular carcinoma and HBV showed that 
fully differentiated liver cells allow complete replication of HBV whereas less 
differentiated cells do not allow replication.  The proliferation of HBV within the 
differentiated cells leads to cell death caused by immune response, and the less 
differentiated cells divided and multiplied in response to the differentiated cell death. 
With such an increased rate of multiplication of cells, chromosomes are more liable to 
 24 
 
sustain mutation effects, which could be perceived as cancer by the host organism’s 
immune system.  Thus, by decreasing the viral load or inhibiting the entry of virus 
into liver cells, the death rate of cells would slow, and ultimately delay the immune 
system response to perceived “cancers”.  This, however, is just one hypothesis about 
how decreasing viral load could mitigate the likelihood of liver carcinoma or other 
diseases (Venkateswaran, Millman, & Blumberg, 1987). 
The results of the paper demonstrated that animals administered with the 
extract showed a significant drop in titer of woodchuck hepatitis antigen, and also that 
the extract was not effective when administered subcutaneously, but was effective 
when administered intraperitoneally. This could be an important piece of information 
to keep in mind when developing extracts for human antiviral studies. After this 
study, there was a wealth of research done to probe antiviral activity and 
hepatoprotective activity of Phyllanthus extracts. 
 
Subsection 2: 2.7.2 P. niruri and HIV 
     Extracts from P. niruri have demonstrated anti-viral behavior, specifically 
against HIV replication.  A study by Naik and Juvekar (2003) assessed the anti-HIV 
effects of alkaloidal extracts of P. niruri on human MT-4 cell lines.  This study 
sought to characterize the pharmacological profile of this plant as well as to 
understand the extent of its antiviral properties. To quantify the antiviral effect, a 
factor called the selectivity index (SI) was employed.   SI is a ratio of how toxic 
Phyllanthus extracts were to viruses with respect to how non-toxic extracts were to 
healthy host cells.  A high SI value indicated high toxicity towards cells infected with 
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virus and low toxicity towards host cells. Compared to the reverse transcriptase 
inhibitor control drug Azidothymidine, which has a SI value of 2046.11, the SI value 
of the Phyllanthus extract was much lower at 13.34. Although the SI of the 
Phyllanthus extract was comparatively low, this value suggests that the extract still 
exhibits some selective toxicity towards virus-infected cells. Naik and Juvekar (2003) 
concluded that P. niruri’s alkaloidal extracts significantly inhibited the growth of 
HIV-1 and HIV-2 on human MT-4 cell lines. 
     Ogata et al. (1992) identified a specific chemical component from P. niruri 
aqueous extracts after discovering its inhibitory effects against HIV-1 reverse 
transcriptase. Using nuclear magnetic resonance spectroscopy (NMR), they matched 
the compound to repandusinic acid A monosodium salt (RA). RA was tested for 
selectivity and found to be 10 times more effective in binding with HIV-1 reverse 
transcriptase versus DNA polymerase alpha. 
     Another active compound, niruriside, was isolated and identified by Qian-
Cutrone et al. (1996) from MeOH extracts of P. niruri leaves. Niruriside was shown 
to significantly inhibit the binding of the REV (regulation of virion expression) 
protein to RRE RNA (REV-responsive element). Qian-Cutrone et al. found that 
niruriside showed specific inhibitory activity against the binding of REV protein to 
RRE  RNA.  REV is responsible for regulating the transport of viral RNA (Gosser et 
al., 2001).  The extraction protocol used in our experiments is an altered niruriside 
extraction methodology outlined by Qian-Cutrone (1996).  Niruriside is classified as a 
saponin, a phytochemical that is similar to the body’s hormones (Chevallier, 1996). It 
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is a colorless powder with molecular formula C38H42O17 and molecular weight 
770.2397 g/mol. 
     There have been various other studies done on extracts of related species in 
the Phyllanthus genus on HIV infection. P. niruri shows potential in treating HIV-1 
and HIV-2 infection. Further research is needed to determine the proper dosage of 
active compounds that will inhibit the virus while not harming human host cells. 
There are numerous other active compounds that could be present in other parts of the 
plant, which could be tested for possible anti-viral properties. 
 
Subsection 3: 2.7.3 Phyllanthus species activity on hepatitis C 
Previous literature has led scientists to conclude that the Phyllanthus genus 
may have an overall positive protective effect on the liver.  However, to date, few 
clinical studies have focused their efforts on the potential effects of Phyllanthus 
species specifically against HCV.  Our project aims to resolve some of the 
shortcomings of these initial studies, including the fact that these few studies tend to 
focus on the therapeutic effects of P. amarus rather than P. niruri.  Because they are 
interrelated species, they may display similar chemical properties. 
Recent studies show that HCV is currently resulting in more fatalities in the 
US than HIV. A 2012 article stated that 3.2 million people have chronic hepatitis C 
virus with over 15,000 people dying from HCV infection in year 2007 (Harmon, 
2012). It’s apparent that HCV is a rising public health crisis that must be addressed by 
both research scientists and public health officials.  
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Hepatitis C is transmitted via blood to blood contact.  Prior to 1992, before 
blood donations were screened for hepatitis C, organ transplants and blood 
transfusions were common ways of spreading HCV (CDC, 2009).  Today, HCV is 
typically spread through drug use and sharing needles, needlestick injuries in health 
care settings, and transmission from a pregnant woman to her baby.  However, 
maternal transmission of HCV is rare, and only 4 out of every 100 infants born to 
mothers with HCV will become infected (CDC, 2009).  Although HCV can be 
transmitted through sexual contact and the sharing of personal care items that may 
have come in contact with blood, the probability of infection in this manner is 
relatively low.  Hepatitis C is not spread through saliva or breastmilk (CDC, 2009). 
The earliest reports of P. amarus on HCV in a standardized laboratory setting 
came from a study on P. amarus root clone activity against bovine viral diarrhea virus 
(BVDV).  BVDV was the popular surrogate model of HCV before the recently-
developed infectious J6JFH system became standard.  BVDV was attractive because 
it was easy to culture, shared a similar structural organization, and caused chronic 
long-term infections in their hosts.  The two viruses also shared other biological 
features, such as LDL receptor mediated endocytosis, internal ribosome entry sites 
(IRES) for translation, and viral enzyme functions (Buckwold, Beer, & Donis, 2003).   
As a result, the BVDV model was a good approximation of HCV in humans.  The 
study revealed that the application P. amarus extracts reduced BVDV-induced 
cytopathic effect (CPE) in a dose-dependent manner.  Therefore, higher 
concentrations of extracts from P. amarus successfully were able to decrease the 
ability of BVDV to kill the cells.  However, this study has a number of shortcomings.  
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Since these extracts were crude and the concentrations that exhibited positive activity 
were so high, their results are not clinically relevant because cells would not be able 
to tolerate such high loads (Bhattacharyya & Bhattacharya, 2003).  Also, the BVDV 
animal model is not as relevant since an infectious human model was established 
several years later in 2006.  Despite these facts, the study may suggest that P. amarus 
and related species may exhibit antiviral effects against HCV.!     
In 2011, Ravikumar et al. conducted cell culture studies with an infectious 
model that confirmed a potential active agent.   A crude methanolic extract of P. 
amarus roots and leaves was obtained, dried, and dissolved in sterile water with 0.2% 
DMSO with final concentrations of 1000 g/mL.  Huh7 cells were infected with HCV 
monocistronic replicon with concentrations ranging from 5-40 g/mL.  P. amarus 
root extract showed significant inhibition of HCV-NS3 protease enzyme and P. 
amarus leaf extract showed considerable inhibition of NS5B in the in vitro assays. 
Viral enzymes NS3 protease and NS5B RNA dependent RNA polymerase are 
essential enzymes for viral RNA replication. Both extracts significantly inhibited the 
replication of HCV monocistronic replicon RNA and HCV H77S viral RNA in HCV 
cell culture system in a dose-dependent manner.  Standard interferon alpha was used 
as a positive control for decreasing viral replication; when standard interferon was 
combined with P. amarus root, the decrease in viral load was an additive effect.  This 
study marks the potential for P. niruri as a potential therapeutic source for hepatitis 
C; however, concentrations as high as 40 g/mL are too high to be applied to clinical 
studies, and the effect of the DMSO vehicle, which was used to dissolve the extracts, 
was not quantified.  It is also difficult to qualify the exact species of Phyllanthus 
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used, but it should be noted that a voucher specimen was stored in their laboratory 
(Ravikumar et al., 2011) 
A clinical trial in February 2011 was also conducted in India, testing P. niruri 
on patients with HCV.  Blood samples were taken from 50 HCV patients before and 
after Phyllanthus administration every week for 10 weeks in order to analyze liver 
profile enzymes, antioxidant enzymes, antioxidant vitamins and lipid peroxidation, 
which are measures of oxidative stress.  As HCV is a major source of oxidative stress, 
these levels serve as an important diagnostic tool.   Based on these tests, it was found 
that therapy with P. amarus increases antioxidants and reduces lipid peroxidation of 
hepatic cellular and intracellular membranes and protects liver damage due to free 
radicals in HCV.  However, this study had tremendous shortcomings.  The dosage per 
patient was not mentioned, as well as the origin of the plant, and whether or not the 
plant was stored as a voucher.  The preparation of the herbal extract was not specified 
and the change in viral load was not indicated.  Viral load must be measured because 
it is possible that the extract may decrease the expression of oxidative stress 
indicators without actually decreasing the viral load.  It is only through a significant 
decrease in viral RNA levels that an effect can be quantified (Nikam, Nikam, 
Sontakke, & Khanwelkar, 2011). 
 
Subsection 4: 2.7.4 HCV Replication 
Current knowledge about the viral replication cycle of HCV is limited because 
an efficient cell culture system or convenient animal model for studying the 
mechanisms has yet to be established (Bartenschlager & Lohmann, 2000). However, 
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since much is known about other closely related viruses in the flavivirus and 
pestivirus families and about the characterization of recombinant HCV proteins, a 
likely method of replication can be theorized (Bartenschlarger & Lohmann, 2000). 
The cycle is outlined in five major steps: 1) penetration of the host cell and injection 
of genomic RNA from the virus particle into the cytoplasm; 2) translation of the 
inserted RNA, processing of the polyprotein and formation of a replicase complex 
associated with intracellular membranes; 3) synthesis of a minus-strand RNA from 
the original, complementary plus-strand RNA; 4) production of new plus-strand RNA 
molecules which in turn can be utilized for the synthesis of new minus strands, for 
polyprotein expression or packaging into progeny virions; 5) release of virus from the 
infected host cell (Bartenschlager & Lohmann, 2000). 
Attachment and entry of the viral particle to the host cell is initiated by 
interaction between the cell surface receptors of the host cell and a viral attachment 
protein on the surface of the virion (Bartenschlager & Lohmann, 2000). The E2 
glycoprotein on the virus particle binds to the CD81 receptor of the surface of the 
host cell (Lindenbach et al., 2005). Whether this initial binding is followed by the 
internalization of the virus particle is an area of research that is still in progress and 
has yet to form a conclusion on this matter (Bartenschlager & Lohmann, 2000). It has 
also been observed that members of the Flaviviridae family may enter the cell by 
binding to low-density lipoprotein (LDL) receptors – the medium of viral genome 




Subsequently, the virus particle enters by endocytosis, which is mediated by 
clathrin-coated pits in the host cell (Moradpour, Penin & Rice, 2007). The endocytic 
pathway of the host cell leads the virus particle (carried via a vesicle) to the viral 
genome’s direct translation. The protein product of this translation is a polyprotein 
precursor that is co- and post- transnationally processed by cellular and viral 
proteases. The final products of this modification are mature structural proteins that 
will be used for the enveloping of replicated viral genomes (Moradpour, Penin & 
Rice, 2007). 
The positive, single-stranded RNA genome, meanwhile, is complemented by a 
negative strand to form an RNA intermediate molecule (Bartenschlager & Lohmann, 
2000). The negative strand then serves as a template for the production of a large 
amount of RNA plus strands (Bartenschlager & Lohmann, 2000). 
The newly synthesized plus strands of RNA are then encapsidated by the viral 
proteins that were produced by the aforementioned polyprotein (Bartenschlager & 
Lohmann, 2000). The specific virion assembly and release mechanism of HCV is 
largely unknown in this stage of viral replication because systems which would allow 
for a biochemical amount of virus particles have been largely absent until quite 
recently (Maradpour, Penin & Rice, 2007). The enzyme NS2 and other non-structural 
proteins are hypothesized to be involved in this process, but no definitive research has 
been conducted to verify this. It is also presumed that virions are formed from 
budding through either the endoplasmic reticulum (ER) of the host-cell or an ER-
derived compartment. Recent research has also proposed the possible link between 
lipoprotein metabolism and viral assembly (Maradpour, Penin, & Rice, 2007). 
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Section 8: 2.8.0 Antioxidants and Hepatoprotective Activity of P. niruri 
The rationale behind our research is that P. niruri can be used in the treatment 
of HCV due to its well-documented activity against liver-related problems and 
diseases.  A bulk of existing literature has focused on the characterization of the 
antioxidant properties of P. niruri and its resulting effects in the liver. In a 2007 
study, researchers in India looked at the antioxidant activity of methanolic extracts of 
five plants from the Phyllanthus genus. While extracts from the five different 
Phyllanthus species exhibited different levels of antioxidant activity, their positive 
activity demonstrated the potential of plants from this genus to be used as natural 
sources of antioxidants (Buckwold, Beer, & Donis, 2003). 
 
Subsection 1: 2.8.1 Overview of Antioxidant and Hepatoprotective Activity  
Antioxidants are defined as molecules capable of inhibiting oxidation of other 
molecules. Oxidation reactions usually produce free radicals or reactive oxygen 
species (ROS) which, when produced within a cell, can cause damage or death to the 
cell. With too many of these molecules within a cell, oxidative stress becomes 
prevalent. Oxidative stress is simply an imbalance between pro-oxidants (harmful) 
and antioxidants which leads to oxidative damage. This damage usually manifests 
itself in the form of DNA, protein, or lipid alteration. Various degenerative diseases 
have been linked to oxidative stress, including cancer, atherosclerosis, and stomach 
ulcers, among others. However, it has been recently reported that cells of patients 
infected with HCV produce an unusual augmentation of oxidative stress due to an 
accumulation of iron within the liver. 
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Experimental models suggest that oxidative stress is involved in the 
pathogenesis of liver diseases (Bjelakovic, et al., 2011). Hepatitis C virus is a blood-
borne pathogen that can cause serious liver diseases such as cirrhosis and 
hepatocellular carcinoma. However, the mechanism through which the virus induces 
pathogenesis remains unclear. A study conducted by de Mochel et al. (2010) 
concluded that hepatocyte proteins are likely to act as a persistent, endogenous source 
of ROS during HCV induced pathogenesis. Another study concluded that the core 
protein of HCV has been shown to induce the overproduction of ROS within the liver 
(Moriya et al. 2010). This has significant implications in terms of treatment options 
for HCV-infected cell populations. Since HCV infection induces oxidative stress and 
stifles antioxidant activation in the liver, this synergistically exacerbates the effects of 
oxidative stress on the liver and facilitates hepatocarcinogenesis. 
Recent studies have been conducted to determine the efficacy of antioxidant 
treatments on HCV-infected cells and/or cells overrun by oxidative stress. The results 
of such studies have surprisingly revealed an array of conclusions. One experiment 
conducted by Nakamura et al. (2010) demonstrated that the antioxidant species 
resveratrol (RVT) actually enhanced HCV replication. This molecule is a natural type 
of phenol produced naturally by several types of plants. Although these findings are 
still debated and discussed, this elicits the notion that not all types of antioxidants 
may protect HCV-infected cells against oxidative stress. Bjelakovic et al. (2011) 
suggested the antioxidants beta-carotene, vitamin A, vitamin C, vitamin E, and 
selenium as potential chemopreventive agents. However, their results were equivocal; 
antioxidant supplements of these species had no significant effects on all-cause 
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mortality or liver-related mortality. On the other hand, Venturini et al. (2010) 
reported that untreated patients with chronic hepatitis C showed lower antioxidant 
capacity and higher levels of pro-oxidant activity. This implies that greater oxidative 
activity could play an important role in pathogenesis and its virulence in the evolution 
of HCV. Untreated patients could thus be treated with particular antioxidants to 
combat the accelerated onset of oxidative stress. Finally, a mitochondria-targeted 
antioxidant known as mitoquinone may decrease necroinflammation in the livers of 
chronic hepatitis C patients (Gane et al,. 2010). Since mitochondrial oxidative 
damage is responsible for other chronic liver diseases, further research in this 
particular direction is warranted. 
 
Subsection 2: 2.8.2 Antioxidants in vitro studies 
Fractions and isolates from P. niruri have been shown to have antioxidant 
effects in-vitro.  Sabir and Rocha in 2008 demonstrated the antioxidative and 
hepatoprotective potential of aqueous extracts of P. niruri.  They induced lipid 
peroxidation of rat liver cells in-vitro using iron and sodium nitroprusside (SNP).  In 
cells treated with iron or SNP, they found that there was a respective 75% or 85% 
increase in the formation of therabarbarbituric acid reactive substance (TBARS), a 
marker of lipid peroxidation which indicates damage to DNA.  P. niruri extracts 
showed protective activity against both iron peroxidation (84.7% protection) and SNP 
peroxidation (61% protection), preventing the increase in levels TBARS. 
Chirdchupunseree and Pramyothin (2010) investigated the protective effect of 
phyllanthin on ethanol induced rat liver cell injury.  Pretreatment of hepatocytes using 
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phyllanthin, a lignan that is a major constituent of the aqueous extract of P. amarus, 
yielded a hepatoprotective effect.   The antioxidant effect of phyllanthin was 
demonstrated by a measured decrease in reactive oxygen species and a restoration of 
levels of key liver enzymes. However, when pretreatment with phyllanthin alone was 
compared with pretreatment using the aqueous extract, it was found that the aqueous 
extract yielded better enhancement, indicating that other phenolic compounds play a 
role in liver protection. 
The protein fraction of P. niruri has also been investigated for its 
antioxidative effect.  Sarkar and Sil (2007) investigated the efficacy of the protein 
isolate of P. niruri against thioacetamide toxicity.  Thioacedamide leads to the 
production of reactive oxygen species (ROS) that increase the rate of lipid 
peroxidation in membranes and can cause the degeneration of DNA.  Sarkar and Sil 
(2007) found that   pretreatment of mice hepatocytes in vitro led to a dose dependent 
increase in cell viability. Interestingly, protein treatment without exposure to 
thioacetamide produced minimal effect, which suggests that protein isolates from P. 
niruri provides a protective effect rather than an enhancement effect. 
Harish and Shivanandappa (2006) found that pretreating rat liver homogenates 
with crude aqueous and methanolic extracts of P. niruri from the fruits and leaves 
inhibited peroxidation due to iron and ascorbate.  Since the leaf and fruit extracts 
contained differing concentrations of phenols, they expected one extract or the other 
to demonstrate more potent antioxidant activity. However, they found little 
correlation between the antioxidant activity and the phenolic content of the extracts, 
which was contradictory to the claim of Chirdchupunseree and Pramyothin (2010). 
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Subsection 3: 2.8.3 Antioxidants in vivo studies 
In a study conducted in 2006, researchers investigated the hepatoprotective 
potential of Phyllanthus niruri against carbon tetrachloride (CCl4) induced liver 
damage. CCl4 is an environmental toxin that causes the formation of trichloromethyl 
and trichloromethyl peroxyl radicals. These radicals are responsible for lipid 
peroxidation that establishes a condition of oxidative stress. This also results in the 
generation of reactive oxygen species (ROS) that alters the enzymatic activity and 
thus cell function. These effects can eventually lead to liver injury, cirrhosis 
development and carcinogenesis. 
Bhattacharjee and Sil (2006) investigated the antioxidant properties of P. 
niruri by using aqueous and methanolic extracts on mice dosed with CCl4. They also 
isolated protein fractions from the aqueous layer as additional methods of treatment.  
Serum levels of hepatic integrity related marker enzymes GPT and ALP were 
measured. Antioxidant enzymes, SOD and CAT, peptide antioxidant (GSH), and lipid 
perioxidation were also measured. Induced toxicity via CCl4 caused the following 
changes: increased levels of GTP and ALP, increase lipid peroxidation, reduced 
levels of SOD and CAT. It was determined that the aqueous fractions of P. niruri 
provided major hepatoprotective activity, and further investigation found that the 
protein isolates in the aqueous extract was partially responsible for this activity. 
Separate trials were run where P. niruri protein fraction was given to mice before 
CCl4 and after CCl4. This examined the preventative and curative role of the protein 
isolate. Results showed that both cases saw increased levels of GPT and ALP as well 
as restored SOD and CAT to normal levels. Since GSH is one of the major defense 
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against oxidative stress, treatment using P. niruri restored GSH levels and reduced 
lipid peroxidation. These results show that P. niruri can significantly rejuvenate 
antioxidative defense mechanisms in damaged liver (Bhattacharjee & Sil, 2006). 
This study of P. niruri in reducing oxidative stress also extends to liver 
damage induced by a non-steroidal anti-inflammatory drug, nimesulide. In these in 
vivo studies, where aqueous extract and protein isolate were also used, researchers 
produced similar results. Nimesulide treatment caused severe deficits in hepatic GSH 
and antioxidant enzymes such as SOD and CAT. Just like the CCl4 study, treatment 
with P. niruri protein fraction caused recovery of the defense mechanisms(Chatterjee, 
Sarkar, & Sil, 2006). 
 
   
 38 
 
Chapter 3: Methodology 
 
Section 1: 3.1.0 Overview 
To address our research questions, our methodology includes several 
interdisciplinary components. First, we germinated and grew our plants with the 
assistance of the US Botanic Garden (USBG) and the University of Maryland 
Greenhouse, with seeds obtained from a trusted online retailer recommended by the 
USBG. After harvesting and obtaining sufficient plant matter, we proceeded with 
chemical extractions. The specific plants used in the extractions were recorded and 
genetically characterized by sequencing genes identified as reliable plant DNA 
barcodes. The extracts were then analyzed in terms of the plant's anti-viral activity in 
cell culture systems. We quantified cell viability and viral load -- the number of RNA 
copies in the culture sample -- using real-time polymerase chain reaction (PCR). 
These parameters determined the efficacy of the treatment.   
  
 
Section 2: 3.2.0 Plant Care and Observation 
Due to the gracious help of the staff at the US Botanic Garden, P. niruri was 
successfully germinated and cultivated for our first and second plant harvests. The 
seeds were obtained from an online vendor, Trade Winds Fruit.  The specific 
harvesting conditions are listed in Appendix A.  On Day 181 are germination, the 
plants were moved to the University of Maryland Greenhouse. The specific growing 
conditions and how the greenhouse conditions were regulated are also listed in 
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Appendix A. The plants were harvested three times (Set 1, 2, and 3) and an alpha 
numeric labeling system was used to match up plants from different harvests to keep 
track of the different plant groups. Detailed observations regarding the plant’s 
reproductive structure were described and photographed with a dissecting 
microscope.   
 
Section 3: 3.3.0 DNA Barcoding 
P. niruri is taxonomically confused with other related species (Duke, 2009). 
DNA barcoding was done on all 19 plant samples to ensure that subsequent 
experiments will be done on the same species of Phyllanthus. Protocols proposed by 
Kress and Erickson (2007), and the rbcL and matK gene combination proposed by 
Hollingsworth et al. (2009) were used because they have produced promising results 
with previous experiments. 
The rbcL-a and matK sequences were the target regions that were amplified to 
generate a barcode for identifying P. niruri.  We decided to focus our regions of 
interest to rbcL and matK because these genes, when combined in barcoding studies, 
showed 72% discrimination of land plant test cases (Hollingsworth et al., 2009). 
Additionally, the Consortium for the Barcode of Life reported in the scientific journal 
Nature that it had chosen rbcL and matK as the approved DNA barcoding regions for 
land plants. PCR, as suggested by Kress and Erickson (2007), was used to amplify the 






Subsection 1: 3.3.1 Sample preparation 
Fresh plant leaves were physically extracted and then lysed with the 
TissueLyser System (Qiagen). Lysed plant cells were subjected to DNA extraction 
via the DNeasy Plant Mini Kit (Qiagen, 2006). All 19 plant samples yield 
concentrated DNA at around 100ng/l concentrations following extraction. DNA 
samples were stored in 1x TE (10mM Tris-Cl pH=8.0, 1mM EDTA pH=8.0) at -20°C 
(Appendix B). 
 
Subsection 2: 3.3.2 Primer Design 
We employed two primer sets published by Hollingsworth et al (2009) in 
order to barcode our samples (Table 2).  Extracted DNA samples were subjected to 
PCR with the following conditions: 95°C for 4 min;  [5 cycles: 94°C for 30 sec ; 
55°C for 1 min ; 72°C for 1 min];  [30 cycles: 94°C for 30 sec; 54°C for 1 min; 72°C 

















Primer sequence (5'-3') 
Erickson rbcLa_f rbcL - 
Forward 
ATGTCACCACAAACAGAGACTAAAGC 





3F_KIM f matk - 
Forward 
CGTACAGTACTTTTGTGTTTACGAG 
  1R_KIM r matk - 
Reverse 
ACCCAGTCCATCTGGAAATCTTGGTTC 
Table 1:  Primer sets used in our study published by Hollingsworth et al (2009). 
 
 
Subsection 3: 3.3.3 Sequencing 
The PCR products were sequenced by GENEWIZ Inc. Both forward and 
reverse sequences were sequenced to ensure accuracy. Raw sequences were cleaned 
with CodonCode to trim ends and locate inaccurate sequence peaks.  
 
Subsection 4: 3.3.4 Sequence Analysis 
 Sequences were aligned with MUSCLE (EMBL-EBI) with default settings. 
Our sequencing data was analyzed through two methods: 1) neighbor-joining tree 
method and 2) BLAST distance method. 
Trees were created with SeaView (Pole Bioinformatique Lyonnais) through a 
neighbor-joining method (Saitou & Nei, 1987).  We pulled 61 additional matK 
Phyllanthus sequences and 36 additional rbcL sequences from the National Center for 
Biotechnology Information (NCBI) database.  These sequences were uploaded to 
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SeaView to reconstruct our phylogenetic tree. Default settings were followed with 
1000 bootstrap replicates and Kimura 2-Parameter distances were established. 
The distance method was done through performing BLAST nucleotide 
searches through NBCI. We BLASTed all cleaned sequences and analyzed the top 
hits. We took into consideration the max identity percentage and max score of each 
hit, and subsequently classified our samples based on these criteria. All specimens of 
P. niruri used in the biochemical analysis and extractions were compared to this 
standard. 
 
Section 4: 3.4.0 Extraction 
Initially we sought to test the Phyllanthus niruri extracts on HIV/HCV co-
infection on different cell lines as a proof of principle that the extract could be applied 
for this particular condition.  As a result, we based our extraction protocol on a 
methanolic extraction outlined in Qian-Cutrone et al. (1996) to isolate a compound 
from Phyllanthus niruri known as nirurside. This compound was found to be active 
against HIV reverse transcriptase, and previous literature review had indicated 
Phyllanthus niruri was considered to be phytochemically active in the liver, held a 
history of activity against hepatitis B, and was long used in Brazilian and Ayurvedic 
medicine.  This provided reason for us to choose this particular extraction protocol, 
because it may have had the potential to be effective on both diseases. However, due 
to time constraints, we only focused on analyzing extracts on HCV but still used the 
niruriside extraction protocol as our base. 
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We modified the Qian-Cutrone extraction protocol to maximize the chances of 
obtaining active fractions and to better suit our purposes and approach, the details of 
which will be explained later. In addition, while only the methanolic and chloroform 
extract were collected in order to isolate niruriside, all fractions from the extraction 
protocol were saved and analyzed.  This meant that both the aqueous and organic 
fractions were saved, since it was shown by Sabir and Rocha (2008) that aqueous 
extractions contained phytochemically active compounds which had in vitro 
antioxidant and in vivo hepatoprotective activity against paracetamol-induced liver 
damage in mice.   
To begin the extraction protocol, the various Phyllanthus were first dried, 
separated and labeled according to their identities. For the extractions, between 5-20 
grams of dried plant matter (anywhere from 10-15 plants), mainly derived from the 
leaves and the stems, were massed.  The alpha numeric code as well as the mass from 
each individual plant used was also recorded. In addition, some of the plant matter 
was reserved for future DNA extraction, PCR, and barcoding. All of the plants used 
for the extraction were from group A, which comprised plants grown and identified as 
P. niruri.  Dried plant matter was ground using a mortar and pestle with 5 milliliters 
of methanol. Since the bark is also considered to be a good source of phytochemicals, 
the stems were also cut up with scissors to aid efficient mashing.  This contrasts with 
the original protocol which used 100 grams of powdered leaves only; a smaller mass 
of leaves were used because the cell studies portion did not require such a high 
concentration of the compound. 
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After maceration, the plant matter was refluxed with around 50 mL of 100% 
methanol for 30 minutes. The plant matter was then filtered out and the dark green 
liquid supernatant was collected in a separate beaker. The plant matter was then 
refluxed again with 50 mL of 80% methanol, and then with 70% methanol, with the 
supernatant filtered between each reflux. 
The extracts were all combined and then heated on low using a hot plate in 
order to evaporate the solvent (Extract 1). Extracts were carefully monitored to ensure 
that they did not burn. This yielded about 350 mg of dark green residue. This residue 
was then re-dissolved in approximately 50 ml of 90% methanol, and then sonicated to 
facilitate dissolving. This solution was then partitioned against around 35-45 mL of 
pure hexane three times. The upper hexane layer was combined with all hexane 
extracts and evaporated on low heat to yield an oily dark green residue (Extract 2). In 
addition, there was a precipitate which formed in the interface between hexane and 
water which was collected and evaporated as well (Extract 2b).  The amount of 
solvent used was scaled down proportionally according to the plant mass used, and a 
few milliliters more or less solvent was added at times depending on how well the 
compounds of the extract were dissolving. 
The lower aqueous layer was then diluted to 75% methanol with 10 mL of 
distilled water. This solution was then partitioned against 35-45 mL of CCl4 three 
times. The lower CCl4 layers were combined and evaporated to yield a dark yellow 
powder (Extract 3). Then the aqueous layer was further diluted to 65% methanol 
solution with 10 mL of distilled water. This was then partitioned three times against 
35-45 mL of CHCl3. The upper methanol layer was evaporated to yield a dark green 
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powder (Extract 4). The lower CHCl3 layer was combined and evaporated to yield a 
light green residue (Extract 5). For future studies, small amounts of each extract in 
their respective solvent were transferred to micro centrifuge tubes for evaporation. 
This yielded around 5-15 mg of dry extract per each tube which could be re-dissolved 
for future studies.  These five crude extracts were later prepared tested on cell 
cultures to evaluate their antiviral activities.  
 
Section 5: 3.5.0 Biochemical Analysis and HPLC analysis of fractions 
After testing all of these extracts on the cells for their activity, our goal was to 
analyze the composition of the extracts that reduced the amount of virus and/or 
increased cell survival. However, even though we know what kinds of compounds 
may possibly be in the plant based on literature search, we could not definitively say 
which specific compounds are present in the extracts. Moreover, we had no way of 
knowing which compounds of the original extract moved to each partition, potentially 
concentrating them and increasing their activity or visa versa. 
Thus, we made an HPLC profile for each extract. Through the HPLC, we 
could compare the phytochemical content across extracts by determining which peaks 
are present and absent in each fraction and how they change in intensity. 
Theoretically, all the peaks present in the un-partitioned methanol extract should 
represent the total compounds which may be present in varying extents in the other 
extracts. Thus, by comparing the chromatograms with each other it should be possible 
to determine what peaks are present in each fraction, and later correlate this to 
activity. Since most of the active compounds contain aromatic rings, we will monitor 
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for absorbance in the aromatic region at 280 nm. While the HPLC method will not 
allow for direct identification of the present compounds, it should at least give us a 
general idea of the distribution of compounds in each fraction.  
We also used analytical HPLC to provide UV spectra to compare unpurified 
fractions to pure fractions. The UV spectra will serve as a map of the contents in the 
whole sample, enabling us to determine which fractions contain active compounds or 
whether multiple solvent extracts contain the same active compound (Appendix G).  
However, again, we could not definitively identify specific compounds.   
For this analysis we used the high performance liquid chromatograph LC-
20AT model equipped with a UV-(SPD-20A) detector, degasser DGU-20As, a low-
pressure gradient unit LC-20AT, a CBM-20A communications bus module, and a C-
18 Luna 5u reverse phase column, 150x4.6 mm by Phenomenex. We also employed a 
Shimadzu Gas Chromatograph GC-2010 equipped with a fused-silica wall-coated 
capillary column and a Shimadzu AOC-20i Auto-Injector controlled by GC Solutions 
software. The GC portion is then coupled with a Shimadzu 2010S Mass 
Spectrometer. To begin, first a small amount of sample is vaporized in the injector 
port and mixed with the inert carrier gas He before being introduced to the column.   
The column employs liquid stationary phase immobilized on a silica support which is 
useable between around 30-300°C and interacts with the volatilized analytes, having a 
higher affinity towards non-polar compound. 
In order to give a more detailed breakdown the contents of the extract we ran 
the extracts diluted in DCM (dichloromethane) through the GCMS (gas 
chromatography-mass spectroscopy). This allowed us to directly determine the mass 
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and potentially the identity of the compounds present in these fractions. Thus we may 
be able to obtain the structure and track the contents of any phytochemically active 
elements of each extract. 
The HPLC extracts were prepared at a concentration of around 1mg/mL in 
DMSO. Since the actual contents of the extracts are unknown, it will not be possible 
to determine an exact concentration. To ensure dissolution, the samples will be 
sonicated and filtered to pellet any undissolved components. Then the sample were 
diluted in water to 0.5 mg/mL and injected onto the HPLC. The solvent composition 
was isocratic at 25:75 acetonitrile:water and a flow rate of 1.00 mL/min for 10 
minutes for each sample run. The un-partitioned methanol extract was run first in 
order to determine whether or not any modification needs to be made to the sample 
procedure. After each run, all of the peaks and their respective areas and retention 
times were determined and cataloged. The detector was set at 254 nm and 280 nm. 
For GCMS, the samples were prepared in a similar fashion but instead using 
CH2Cl2 as the solvent. Again, sonication and filtration of the samples was done to 
ensure no precipitate was injected on the column. We ran on a temperature ramp from 
100-250°C for fifteen minutes, with the last five minutes holding at 250°C. The 
sample chromatograms will then be run through the library data to search for any 
matching compounds at various peaks. 
By repeatedly refining the extracts, their chemical compositions will become 
more defined, thus enabling us to better pinpoint the antiviral activity of specific 
compounds and identify their chemical structures.  If an active compound can be 
isolated, its structure can be determined through NMR and IR spectroscopy, but this 
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likely will be reserved for future studies as it does not fit into the scope of this project 
(Lambert, Shurvell, Lightner, & Cooks, 1998). 
 
Section 6: 3.6.0 Extract Preparation  
Plant extracts from five separate extractions, labeled Extract 1 to 5, were 
dissolved in dimethyl-sulfoxide (DMSO) using a sonicator in an ultrasonic bath. 
Sonicators break intermolecular reactions between chemicals, which helped break up 
the sticky extract product in DMSO. The weight of the extract prior to dissolution 
was measured so that the final concentration could be calculated in micrograms per 
milliliter. Because the extract was so sticky, it was crucial that all of the extract was 
dissolved to be able to determine the final concentration accurately, which is why the 
sonicator was used.  
Overall, each extract dissolved in 10-12 mL of DMSO, depending on their 
ability to be dissolved in DMSO (Table 3). The dissolved extracts were vortexed 
vigorously, divided into 1 mL aliquots in microcentrifuge tubes, and frozen at -80C.  
To prepare them for application to cell culture, each extract aliquot was defrosted and 
dissolved in enough DMEM (Dulbecco's Modified Eagle's Medium) to make 1000 
g/mL stock solution.  Six more tenfold dilutions were made from this stock solution 
with DMEM, including 100 g/mL, 10 g/mL, 1 g/mL, 0.1 g/mL, 0.01 g/mL, 






Extract Mass of 
extract 
(grams) 




added to extract 
(ml) 
Concentration after 
dissolve in DMSO 
(µg/mL)  
1 0.108 1.08 x 10
5 10 1.08 x 104 
2 0.035 3.5 x 10
4 10 3.5 x 103 
3 0.170 1.70 x 10
5 10 1.70 x 104 
4 0.400 4.00 x 10
5 10 4.00 x 104 
5 0.140 1.40 x 10
5 12 1.17 x 104 
 Table 2: Extracts concentrations after diluted in DMSO. 
 
Section 7: 3.7.0  Cell activities studies objective 
Using in vitro cell culture systems, tested the efficacy of different P. niruri 
extracts on HCV. Specifically, our experiment hopes to elucidate the effect, if any, of 
P. niruri plant extracts on HCV viral load and cell toxicity. By quantifying this effect, 
we can make conclusions regarding therapeutic potential of the plant, extract fractions 
most likely to contain active compounds, and whether this plant warrants future 
research to investigate its medicinal properties.  
 
Subsection 1: 3.7.1 Cell Line  
We use the Huh7.5 liver cancer cell line, which begin as uninfected liver cells.  
In order to generate an infectious cell line, the cells must transfected with a J6/JFH1 
genotype 2a virus strain in which JFH stands for Japanese fulminant hepatitis.   Once 
transfected with J6/JFH1 genotype 2a virus, the infected cells are referred to by the 
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name of the virus, or J6JFH cells. Although the liver is not normally in a cancerous 
state when infected with HCV, this system is the one of the few in existence that can 
produce an infectious system.  Past systems only had success infecting the cells once, 
but infected cells could not continue the infection and spread the virus to other cells 
(Bartenschlager & Sparacio, 2007).  Furthermore, because the cell study is in vitro, 
application of the results to therapy may prove difficult. Cells often behave 
differently in vivo as opposed to in vitro due to biochemical pathways that cannot be 
properly represented in cell culture media. Similarly, wild-type HCV strains have not 
been as well experimented as lab-grown HCV strains so that therapies for in vitro 
strains may not be as effective to in vivo strains. 
 
Subsection 2: 3.7.2 Kinetics experiment overview 
We conducted a time-course (kinetics) experiment, in which we studied the 
change in virus levels and cell death over time due to our plant extract. The 
experiment ran for four days, and we took samples of viability and viral load on 24 
hours, 48 hours, and 96 hours. On each day, we determined the viral load (how much 
virus is present in the cell) and cell viability (how many cells are alive). Viral load 
was quantified by extracting RNA from the cell-secreted supernatant. Quantitative 
real-time PCR (qT-PCR) estimated viral sample concentrations through comparison 
with a standard curve, which contains a set of viral-RNA dilutions in which the 
number of viral RNA copies is known. As for quantifying cell viability, we used an 
MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-
2H-tetrazolium) assay, which applies a dye metabolized only by living cells. When 
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cells take up the dye, the medium changes color, and the number of viable cells 
becomes directly proportional to the degree of color change. This color change was 
measured by absorbance optical density values from a spectrophotometer (Promega, 
2009). 
If our extracts were active against the virus, we expected that the viral load 
would decrease and cell viability would remain high. In order words, the amount of 
virus in the cell should decrease and the cells should stay alive. An extract may be 
toxic to the cell, so its anti-viral properties must be balanced with its toxicity to the 
cell. We tested various concentrations of our extract, based on mass of plant sample 
per volume of solvent. The initial extracts were dissolved in dimethyl sulfoxide and 
then diluted in DMEM with 1% penicillin/streptomycin and 10% fetal bovine serum 
before application to cell culture. Our positive control in the experiment was an agent 
known to decrease viral load without killing the cells. It is currently prescribed in 
treatment and known as interferon-alpha. Our negative control had no treatment, 
which served to confirm that our positive control worked and to provide a baseline to 
analyze the effect of our treatment. Our second negative control was the DMSO and 
medium, in order to account for the fact that the observed effect may be due to the 
DMSO solvent itself rather than the extracts. Through this experiment, we found the 
optimal concentration for different extracts that is effective in both keeping the cells 




Subsection 3: 3.7.3 MTS Assay 
To measure cell viability, a MTS assay from Promega was used (CellTiter 
96® AQueous One Solution Cell Proliferation Assay System). MTS assay was 
chosen over MTT assay because MTS produced a soluble compound when reduced 
by cells. Thus, no other reagent was needed to dissolve the crystals, like those formed 
in the MTT assay. 
Ten 96 well culture plates were used to analyze cell viability at 24 hours, 48 
hours, and 96 hours. Three plates were designated as the control plates, one for each 
time point. The control plates contained DMSO diluted in medium, interferon (10 
IU/ml) in medium, or medium over infected and uninfected cells. DMSO diluted 
medium to act as the DMSO vehicle control. This is to account for the fact that 
DMSO itself as a solvent for the extracts may have an effect on the viral load or cell 
viability.  By measuring the effect of DMSO and using it as a baseline in data 
analysis, we could distinguish the effect of the extract from the effect of DMSO. 
Since not all extracts had the same concentration of DMSO solvent, the levels of 
DMSO in the DMSO vehicle control corresponded to highest DMSO level 
concentrations used in extracts. For example, Extract 2 had the highest amount of 
DMSO, with 28.5 l of DMSO dissolved in 971.5 l of medium used to make 100 
µg/mL concentration of extract.  Similarly, the DMSO control had 28.5 l of DMSO 
in 971.5 l of medium.  At 10 µg/mL, the amount of DMSO was diluted tenfold in 
the extract, and this was also done in the DMSO vehicle control.  Essentially for each 
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extract concentration, a DMSO control corresponded to it with proportional levels of 
DMSO. 
For each time point, two plates were designated as the experimental plates, 
which contained plant extract dissolved in medium over infected or uninfected cells.  
Each concentration for each extract was plated in triplicates. One plate was 
designated for the standard curve, in which cell of known quantities were plated 
(40,000 cells, 20,000 cells, 10,000 cells, 5,000 cells, 2,500 cells, and 1,250 cells). By 
having a standard curve, an equation could be developed to link the absorbance 
values to the number of cells, so that the absorbance values from our experimental 
samples could be calculated into the number of cells. The absorbance of these cells 
was measured at day 0. A table of each plate layout is included in Appendix K. 
Roughly 5000 cells in 100 l medium were plated in each well at time zero. 
After 24 hours, the cells would have attached to the bottom of the plate. At this time, 
medium was removed and 100 l of the appropriate amount of extract or controls 
were added. To test if extracts and interferon had any significant effects together, this 
100 l was divided so 50 l of extract was combined with 50 l of 10 IU/ml 
interferon alpha for concentrations ranging tenfold from 0.001 µg/mL 10 µg/mL. 
Quantifying cell viability was done by adding 20 l of Owen’s Reagent (3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) to each well 3 hours 
before their designated time for absorbance measurements. This compound is 
bioreduced to soluble formazan by metabolically active cells. Thus, the reagent was 
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added at 21 hours for the day 1 plate, 45 hours for the day 2 plates, and 93 hours for 
the day 4 plates. Owen’s reagent was allowed to incubate with the cells for 3 hours to 
allow color change from yellow to purple to take place. For complete protocol on this 
cell viability assay, refer to Appendix B (CellTiter 96® AQueous One Solution Cell 
Proliferation Assay) 
Reaction product in each 96 well plate was measured using a microplate 
reader set at 490nm on a SpectraMax Plus384 Plate reader. The microplate reader 
was blanked using a solution of medium and Owen’s Reagent. Then, each well plate 
was placed in the reader, which measures the absorbance of 490nm light through each 
well. Light, at the given wavelength, was shined through each well from the top. A 
sensor beneath the wells measure the percent of light transmitted through the wells. 
Data from the microplate reader was analyzed using a SoftMax Pro software. Using 
this data, a graph could be produced based on Beer’s Law (optical density= ecl) 
Where optical density represents the absorbance, ‘e’ is the extinction coefficient, ‘c’ 
is the concentration of the solution being measured, and ‘l’ is the path length of the 
light through the well. 
 
Subsection 4: 3.7.4 Viral Load Assay  
         A 6-well plate was used for each of the 5 separate plant extractions as well as 
a control plate with only DMSO and infected cells with J6/JFH genotype 2a virus. On 
each plate, 105 cells were loaded per well. Then, each well was loaded with a 
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different amount of plant extract: 10 µg/mL, 1µg/mL, 100ng/ml, 10ng/ml, 1ng/ml, 
and  10 IU/ml IFN-. The highest concentration (100 µg/mL) was not used because 
the amount of DMSO needed to dissolve the product was too high, and from viability 
assays, we found that DMSO had a toxic effect on cells. In addition, concentrations 
that high are unrealistic for clinical application. The IFN- well served as a positive 
control because this compound is known to suppress viral RNA replication. The 5 
extractions, their concentrations, and the control samples were plated in triplicates, so 
that samples could be collected at 24 hours, 48 hours, and 96 hours. By samples, we 
refer to the collection of supernatant or cell medium and the collection of cellular 
RNA. All samples were stored at -80 C conditions until their viral RNA could be 
extracted at a later time. 
After viral RNA from supernatant was collected, it was extracted and purified 
using QIAamp MinElute Spin Kit and following the protocol outlined in QIAamp 
Viral RNA mini Handbook pages 23-26 following the spin protocol.  However, the 
amount of cells used the extraction was triple of the amount stated in the handbook. 
The handbook states to use 140 l of sample, so our tripled amount was 420 l. The 
amount of buffer used was also tripled as recommended in the handbook protocol.  
This tripling of the protocol is required in order to get enough viral RNA.  Viral RNA 
was eluted in 60 ul of Buffer AVE. 
Supernatant Viral RNA was then quantified through quantitative real-time 
PCR, in which a fluorescent probe recognizes the viral RNA sequence.  Through 
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TaqMan® One-Step RT-PCR Master Mix Reagents Kit, viral RNA extracted from 
the supernatant is converted to complementary DNA (cDNA).  The probe attaches to 
the cDNA viral RNA sequence, and upon the sequence of the cDNA’s 
complementary DNA strand, Taq polymerase will run into the probe.  The probe will 
be cleaved, causing it to fluoresce. The amount of light released from the probe 
corresponds to the concentration of viral RNA, and compared to a standard curve of 
known RNA copies, the amount of viral RNA can be interpolated (Appendix B). 
 
Section 8: 3.8.0 Data Analysis methods for cell data 
 In order to analyze the cell data, the number of viral copies per cell had to be 
calculated because it was later discovered that the extracts influenced the number of 
cells significantly.  Due to this effect, simply comparing the number of viral load 
between extracts and control would not be an accurate representation of the effect of 
the extract. To calculate the number of viral copies per cell, the MTS data was 
integrated with the viral load data. 
 5000 cells were plated in the MTS assay and 100,000 cells were used in the 
viral load assay, so the changes in the number of cells observed in the MTS assay was 
multiplied by a factor 20 in order to estimate the possible number of cells that would 
be present in the viral load assay.  For example, if the number of cells had changed 
from 5000 to 6000 cells, in the viral load assay, we can estimate the the cells would 
behave the same way, and the number of cells would change from 100,000 to 120,000 
cells.  This calculation served as the number of cells.   
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For the viral load, based on the quantitative real-time PCR protocol used, 8 ul 
of the extracted viral RNA from each extract was measured for viral load. These 8 ul 
came from an elution of 60 l.  Each 60 l elution came from 420 ul of viral 
supernatant, which came from 1.5 ml of viral supernatant in the viral load assay. 
Once the viral load was scaled up to account for all of these factors, the total amount 
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l = C * 
60/8 
E: Viral load 









4596.1 91,922.5 175,543 1,316,572.5 4,702,044.6 51.1 
Table 3: Data calculations for viral load per cell 
 
 The viral load per cell was calculated three times due to the fact that triplicates 
were used in the experiments. After the above calculations were completed, the 
percent difference in viral copies/cell was calculated via the percent change formula 
((experimental value - control value)/(control value) * 100%).  The standard error 
was also calculated and used in all data sets. The student t-test was used throughout 
for tests for significance between different samples (alpha = 0.05). 
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Chapter 4: Results 
 
Section 1: 4.1.0 Plant Structure 
High resolution pictures were taken with an AxioCamHR microscope camera 
(Carl Zeiss) to elucidate the physical structure of P. niruri.  We were able to capture 
structures of the male flower, female flower, cross-sections of the capsule, and leaves. 
We used these images to compare the plants grown for this study with the 
documented taxonomy of known P. niruri.  
Overall, we observed from maturation of the capsule that male and female 
flowers were coupled, and more mature capsules were located closer to the stem as 
shown in Figure 1(e). When the capsule reached a certain maturation point, the male 
flower was no longer present. In addition, as the plant matured the stem became 
woodier, especially towards the root end of the plant.  Female flowers were observed 
to have five or six petals, with a single flower in the center that consisted of a pedicel, 
three-parted ovary (Figure 1c, f, g).  The petals in female flowers were white with a 
dark green stripe down the center with a lighter green stripe on either side of the dark 
green stripe; the flower petals came to a triangular point, in comparison to male 
flowers which were rounded (Figure 1a).  The capsule was very small, approximately 
2 mm in length. A few male flowers were observed to have five petals although it is 
known that six petals were also possible.  The characteristics of the male flowers 
were hard to elucidate due its small size, even under the microscope; it was observed 
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that the stamens are yellow.  Three leaves were measured for the length, and they 
were about 5-6 mm (Figure 1d).  
 
 
Figure 1: Major physical features of P. niruri leaf and reproductive structure were 
photographed and documented with an AxioCamHR microscope camera (Carl Zeiss), 
in order to provide physical descriptions linked to the DNA barcode.  The following 
structures were identified (a) male flower (b) female flower (c) capsule cross-section 
(d) leaves (e) branch of P. niruri (f) female flower with six petals and (g) female 





Section 2: 4.2.0 DNA Barcoding 
Subsection 1: 4.2.1 PCR and alignment 
Both matk and rbcl primer sets were successful in the amplification of 
extracted DNA samples. All 19 samples produced distinct bands at 1kb for the matk 
primer set. Similarly, 18 of the 19 samples produced distinct bands at 700bp for the 
rbcl primer set. Only sample number 49 failed to amplify rbcL with the standardized 
PCR conditions. 
Figure 2: Successful PCR amplification of 19 P. niruri gDNA samples with (a) matk 




Sample 49 failed at other test conditions for rbcl, thus we proceeded with tree 
analysis with only matk region for this sample (Figure 2b).  Matk sequences revealed 












































Figure 3: Phylogenetic tree of Phyllanthus matK sequences show that all 19 samples 
most closely align with P. amarus.  The tree was created with SeaView with 1000 





Figure 4: Phylogenetic tree of Phyllanthus rbcl sequences show that all 19 samples 
closely align with Phyllanthus amarus and P.niruri. The next closest neighbors are P. 
nummulariifolius and P. tenellus. The tree was created with SeaView with 1000 




All 19 matk sequences were mapped most closely with P. amarus (Figure 3). 
P. niruri was mapped on a completely separate branch rooted at the base of the tree. 
The next closest related ancestors to our samples are P. tenellus and P. 
nummulariifolius. P. niruri was mapped most closely to P. fliutans, P. caroliniensis, P. 
claussenii, and P. klotzschianus.  
      The 19 rbcL sequences were mapped to P. amarus and P. niruri (Figure 4). 
The next closest tree neighbors are P. nummulariifolius and P. tenellus.  These were 
done with 1000 bootstrap replicates using default distance methods.   
 
Subsection 3: 4.2.3 Distance-based assignment shows matches with P. niruri and P. 
amarus 
 
 The BLAST (NCBI) distance based approached showed our rbcL sequences 
to be most similar to P. niruri voucher PS0215MT01 ribulose-1,5-bisphosphate 
carboxylase/oxygenase large subunit (rbcL) gene from the chloroplast (Figure 5). A 
neighbor joining method was used to create the subsequent tree of the top BLAST 
hits with a max sequence difference of 0.75.  The next closest neighbor of our 
samples as mapped by rbcL is Phyllanthus amarus ribulose-1,5 -bisphosphate 




Figure 5: Neighbor-joining tree of Phyllanthus rbcL sequences shows that all 19 samples most closely align with P. niruri voucher 
PS0215MT01 ribulose-1,5-bisphosphate carboxylase/oxygenase large subunit (rbcL) gene, partial cds; chloroplast.  The next closest 
neighbor is Phyllanthus amarus ribulose-1,5-bisphosphate carboxylase/oxygenase large subunit (rbcL) gene, partial cds; chloroplast. 




The matK sequences were found to be most similar to P. amarus maturase K 
(matK) gene, partial cds (Figure 6). The next closest neighbor is P. amarus voucher 
Philcox 7651 trnK gene, partial sequence and matK gene, complete cds. No P. niruri 
hits were observed with the default BLAST settings. P. niruri hits were not observed 




Figure 6: Neighbor-joining tree of Phyllanthus matK sequences show that all 19 samples most closely align with P. amarus maturase 
K (matK) gene, partial cds; plastid. The next closest neighbor is P. amarus voucher Philcox 7651 trnK gene, partial sequence and 
matK gene, complete cds; chloroplast. The tree was generated through BLAST (NCBI) pairwise alignments using a max sequence 
difference of 0.75. 
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Both the tree-based and distance-based methods revealed similar results as reflected 
by their phylogenetic trees. 
 
Section 3: 4.3.0 Extractions and HPLC analysis of fractions 
         The HPLC data chromatograms are included in Appendix L. It provided 
interesting information about the composition of each fraction. Table 4a and 4b 
summarizes the results found. 
Table 4a : Below is the summarized data for the HPLC reports. Each set of peak 
areas are grouped relative to retention times (Rt) approximately. The table is split into 














254 1 1.136 42847 2.156 69826     2.756 325108     
280                       
254 2     2.284 14494     2.752 13210     
280       2.279 30314             
254 3         2.486 12929         
280           2.481 14888         
254 4         2.631 455804  2.81 862804   
280           2.633  374112  2.829 91643 3.037  802205  
254 5         2.631 49069 2.97 37647  3.092  18730 
















254 1 3.189 264974 3.59 206447         
280                   
254 2         3.829 350523 8.324 7141653 
280   3.256 353447         8.338 165890 
254 3     3.632 113080 3.971 46013     
280   3.235 105624 3.566 143199         
254 4               
280                 
254 5 3.226  108684             
280   3.302 478741             
          
 
Each extract displayed a different chromatographic profile and overall peak 
distribution. The information yielded from the detector at 280 nm showed that there 
are very few compounds with aromatic systems in our samples, as these peaks were 
minimal. Most informative was the detector data at 254 nm which gave a distinct 
profile of each extract. It is important to note that similar retention times across peaks 
likely means that the compound contained in that peak was present in multiple 
extracts. This is likely due to a lack of preference for one solvent over the other 
during the partitioning process.  In addition, the retention times, which should be 
identical for each compound, were not entirely conserved.  This could mean that the 
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peaks were of different compounds, or simply that the large amount of compounds 
shifted the over all retention time. 
Unfortunately, the composition of the extracts was not ideal for running on 
GCMS and we were unable to get any significant data from this trial. This was either 
due to the fact that CH2Cl2 could not dissolve enough sample to merit detection, or 
more likely that the boiling points of most of the compounds were above the level 
where they could be separated on GCMS. This data was not included in the report. 
 
Section 4: 4.4.0 The effect of P. niruri extracts on HCV viral copies per cell 
In order to analyze the effects of P. niruri extracts on hepatitis C replication, 
the viral copies per cell was calculated for HCV-infected cells with treatment and 
without treatment.  Because we found that the number of cells changed due to the 
extract (the data for which will be shown in Figure 11a-c), the viral load per cell was 
a more useful indicator to compare samples than the viral load alone.  Based on the 
percent change in the viral copies per cell between treated and untreated cells, it was 
possible to identify the most effective concentrations for Extracts 1 to 5 and compare 
their effect with that of standard interferon, which is displayed in Figure 7.  This 
percent change is also referred to as the percent suppression.  
The suppression of HCV over time does not change very much for Extract 1 at 
0.001 g/mL and Extract 2 at 0.001 g/mL.  As seen in Figure 7, suppression from 
Extract 1 at 0.001 g/mL ranges from 67.4% to 79.4% from 24 to 96 hours, and while 
Extract 2 at 0.001 g/mL experiences a wider range from 67.0-88.5%, it is not much 
larger.  Other extracts, however, show different behavior.  Both Extract 3 at 1 g/mL 
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and Extract 4 at 10 g/mL exhibit strong suppression early that does not last over 
time, but the slope of this decline is different between these two extracts.  Extract 3 
experiences a slower initial decline, changing from 70.3% to 66.7% suppression from 
24 to 48 hours.  However, by 96 hours, the suppression effect dropped by half.  
Extract 4 at 10 g/mL exhibits the strongest suppression of HCV viral copies per cell 
at 24 hours reaching 99.35% suppression, but the effect drops off more quickly.  
Suppression is 59% at 48 hours and later falls to 42% by 96 hours. Very high 
suppression is also seen in extract 5 at 10 g/mL and standard interferon alpha (10 
IU/ml), but their behavior varies from Extracts 3 and 4.  In these samples, the effect 
of suppression is not observed initially, showing 8-12% suppression at 24 hours, but 
it increases over time, reaching 99.94% and 93.70% suppression, respectively, by 96 
hours.  
At 24 hours, Extract 1, Extract 2, and Extract 3 do not demonstrate significant 
changes in HCV suppression among concentrations.  The suppression for these 
extracts narrowly ranges from 62.7%-82.7% consistently across these extracts, which 
may indicate that a wider range of concentrations may be need to have been tested in 
order for a behavior pattern to be more clearly qualified.  For extract 4, at 10 g/mL, 
there is initial strong suppression at 99.35%, but this effect drops drastically to 15.3% 
as the concentration decreases to 1 g/mL before increasing back up to 60-70% 
suppression. This could be an indication of solubility issues, a fluke, or a error in the 
instrument while reading this time point.  However, as concentrations decreased, 
activity returned in a dose-dependent manner.  For Extract 5, the suppression varies 
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widely, such that no pattern can be reasonably demonstrated, which may indicate 
particular flaws with reading this particular time point (Figure 7) .  
At 48 hours, in general, the effect across concentrations of all extracts is 
between 53.9%-87.2%, except for Extract 5 0.001 g/mL.  This concentration had 
36.2% suppression against HCV although there is large variation in this data point.  
There seems to be little variation in the activity across concentrations, and although 
extracts do experience dips in activity across concentrations at certain points, the 
error bars overlap too closely to be able to say a discernible difference exists between 
samples.  Extract 1 dips in its effect on HCV viral suppression at 0.01 g/mL, which 
like the extracts at 24 hours, may be an indication of solubility problems Extract 5 at 
0.001 g/mL has significant error in its reading, which may be due to larger variation 
in the number of cells for the calculation of number of viral copies per cell. 
At 96 hours, across concentrations of each extract, we begin to see the 
behavior of the extracts more clearly elucidated over time.  For Extract 1, in general, 
the suppression had not changed significantly from 48 hours or 24 hours, staying 
within approximately 60-80% suppression.  This may indicate that the effect may be 
longer-lasting.  At 0.01 g/mL and 0.1 g/mL for Extract 1, there is a dip in the 
effectiveness of the extract.  This may be an indication of solubility issues, a fluke, or 
an error in the instrument while reading this time point, since as concentrations 
increased, activity returned in a dose-dependent manner.  For Extract 2, similar 
behavior occurs at 1 g/mL, but it exhibits the opposite behavior as Extract 1.  As 
concentrations decreased, the suppression increased again in a dose-dependent 
manner.  For Extracts 3 and 4, the suppression of HCV was strong initially, but over 
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time by 96 hours, the effect was not sustained.  At 96 hours, these two extracts are the 
weakest of all five extracts to suppress the number of HCV viral copies per cell, and 
nearly half the strength of Extract 5.  For Extract 5, it displays the most clear dose 
dependent effect that as concentrations decreased, the antiviral effect of the extracts 
increased from near complete suppression at 10 g/mL to no suppression at 8% at 





Figure 7: HCV-infected Huh7.5 cells were treated with P. niruri extracts for four days. The number of cells and viral load was 
measured at 24, 48, and 96 hours with MTS assay and quantitative real-time PCR respectively, after which the viral copies per cell 
was calculated.  Based on the percent change in the viral copies per cell between the extract-treated cells and untreated infected cells, 
the following results were obtained for extracts 1-5 and standard interferon.  Only the most effective concentrations from each extract 
are displayed.  Different extracts differ in their effect on the number of HCV viral copies per cell.  
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Subsection 1: 4.4.1 The effect of P. niruri extracts on HCV viral copies per cell over 
concentrations at each time point 
 
It was also possible to look at the changes in suppression over extract 
concentrations at each time point, as seen in Figure 8a-c. At 24 hours, Extract 1, 
Extract 2, and Extract 3 do not demonstrate significant changes in HCV suppression 
among concentrations.  The suppression has a narrow range from 62.7%-82.7% 
across these extracts, which may indicate that a wider range of concentrations should 
have been tested in order for a more significant dose-dependent pattern to emerge.  
For Extract 4, at 10 g/mL, there was initial strong suppression at 99.35%, but this 
effect drops drastically to 15.3% as the concentration decreases to 1 µg/ml before 
increasing back up to 60-70% suppression. This could be an indication of solubility 
issues, a fluke, or an error in the instrument while reading this time point.  However, 
as concentrations decreases, activity returns in a dose-dependent manner.  For Extract 
5, the suppression varies widely, such that no pattern can be reasonably demonstrated, 
which may indicate particular flaws with reading this particular time point.  
At 48 hours (Figure 8b), there seems to be little variation in the activity across 
concentrations. Although extracts do experience dips in activity across concentrations 
at certain points, the error bars overlap too closely to be able to say a discernible 
difference exists between samples.  Extract 1 dips in its effect on HCV viral 
suppression at 0.01 g/mL, which like the extracts at 24 hours, may be an indication 
of solubility problems Extract 5 at 0.001 g/mL has significant error in its reading, 
which may be due to larger variation in the number of cells for the calculation of 
number of viral copies per cell. 
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At 96 hours (Figure 8c), across concentrations of each extract, we begin to see 
the behavior of the extracts more clearly elucidates over time.  For Extract 1, in 
general, the suppression had not changed significantly from 48 hours or 24 hours, 
which may indicate the the effect may be longer-lasting.  At 0.01 g/mL and 0.1 
g/mL for Extract 1, there is a dip in the effectiveness of the extract.  Since 
concentrations increase as activity returned in a dose-dependent manner, this may be 
an indication of solubility issues or an error in the instrument while reading this time 
point. For Extract 2, similar behavior occurs at 1 g/mL, but it exhibits the opposite 
behavior as Extract 1.  As concentrations decreases, the suppression increases again.  
For Extracts 3 and 4, the suppression of HCV was strong initially, but over time by 96 
hours, as indicated here, the effect was not sustained. At 96 hours, these two extracts 
are the weakest of all five extracts to suppress the number of HCV viral copies per 
cell, and nearly half that of Extract 5.  For Extract 5, it displays the most clear dose 
dependent effect, that as concentrations decreases, the antiviral effect of the extracts 




Figure 8a-c: Suppression of HCV viral copies/cell by P. niruri at different time points. The suppression of viral copies per cell 
changes over concentrations at a single time point.  The behavior of different extracts is presented at 24 hours (8a), 48 hours (8b), 96 





Figure 8a-c: Suppression of HCV viral copies/cell by P. niruri at different time points. The suppression of viral copies per cell 
changes over concentrations at a single time point.  The behavior of different extracts is presented at 24 hours (8a), 48 hours (8b), 96 





Figure 8a-c: Suppression of HCV viral copies/cell by P. niruri at different time points. The suppression of viral copies per cell 
changes over concentrations at a single time point.  The behavior of different extracts is presented at 24 hours (8a), 48 hours (8b), 96 
hours (8c).  
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Subsection 2: 4.4.2 The effect of P. niruri on Huh7.5 cells survival  
In order to assess the toxicity of the extracts on cell cultures, all 
concentrations of extract are tested on Huh7.5 uninfected liver cancer cells.  The data 
for toxicity came from the MTS assay.  Two trials of the MTS assay are done.  In the 
first trial, the MTS assay experimental design failed to include the standard curve at 
day 0 and other controls, namely purely untreated cells (Huh7.5 cells and J6JFH 
cells) with medium only. However, this first trial allows for assessment of what 
effects the extracts have with respect to DMSO, and a change in the number of cells 
was not expected. These initial results indicated that there was a change in the cell 
number from the DMSO control, and that there was enough reason to believe 
Phyllanthus showing activity and not the DMSO. Thus, the second trial conducted 
includes untreated controls. 
Based on the second trial of the MTS assay, we find that the effect of P. niruri 
extracts on Huh7.5 cells survival is not significant (p > 0.05 for all concentrations 
tested) at 24 hours to increase the viability of Huh7.5 cells, except for Extract 1 and 
lower concentrations (0.001 g/mL and 0.01 g/mL) of Extract 2 after 24 hours 
where p < 0.05. Results from the five extracts on uninfected Huh7.5 cell cultures for 
24 hours are shown in Figure 9a. All extracts, with the exception of Extract 4, have an 
increase in percent growth for treated Huh7.5 cells versus untreated cells. Extract 4 
showed a decrease in cell viability that increases gradually as concentrations increase. 
Overall, at 24 hours incubation, the percent change for each extract stays relatively 
consistent over the range of concentrations.  
For 48 hours, the ability of extracts to increase the viability of Huh7.5 cell 
survival varied greatly. Extracts 1, 2, and 3 showed no great significance as the p-
 81 
 
value varies spontaneously across different concentrations. Extract 4 significantly 
increases cell viability in concentrations of 1 g/mL, 10 g/mL, and 100 g/mL. Four 
out of six concentrations tested for Extract 5 are significant according to p < 0.05. In 
Figure 9 below, Extract 1 and 4 have positive percent increase for treated cells versus 
untreated cells. Extracts 2 and 3 show no negative changes in cell viability at low 
concentrations while at high concentrations, there is a negative percent change in 
treated cells with respect to non-treated cells. Extract 5 shows a negative percent 
change at low concentrations of 0.001 g/mL and 0.01 g/mL, while positive percent 
changes in cell growth in concentrations of 0.1 g/mL and greater.  
In the 96-hour Huh7.5 cell cultures, Extracts 1 and 2 significantly increase cell 
viability at high concentrations (10 g/mL) for Extract 1 and 10 g/mL for Extract 2.  
Extract 4 was significant in affecting cell viability for 0.001 g/mL as well as 10 
g/mL and 100 g/mL. Extract 5 only proved significant at 10 g/mL. All other 
concentrations for extracts were found to be insignificant in regards of cell viability. 
In the 96-hour Huh7.5 graph (Figure 9c), all extracts had a positive effect on cell 
growth in treated cell cultures in concentrations of 10g/mL and lower. At 
100g/mL, all extracts significantly decreases cell growth to various degrees, 
possibly due to the higher levels of DMSO. Extract 2 and 3 had the largest effect on 
cell growth at 100g/mL, with a decrease in cell growth in treated vs. untreated 
difference of 83% and 82% respectively.   
Overall, over time, the effect of extracts on cells did not seem to have a 
negative impact on the number of cells.  Either the number of cells was often 
comparable or significantly greater under the influence of the extracts, but often not 
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less than the number of cells in the untreated sample, unless the extract was at very 
high concentrations with higher levels of DMSO.  This relationship can perhaps most 
easily be seen with Figure 10a-e, which shows the change in the number of cells over 
time due to the effect of different concentrations of a single extract in comparison to 
untreated cells.  Quadratic regression curves show that the number of viable cells is 







Figure 9a-c: Percent change in cell growth between uninfected treated and uninfected untreated Huh7.5 cells when treated with P. 
niruri extracts 1, 2, 3, 4, and 5 in concentrations of 0.001, 0.01, 0.1, 1, 10, and 100 g/mL for (a) 24 hours, (b) 48 hours, and (c) 96 
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Figure 10a-e.  Change in the number of cells over four day treatment of Huh7.5 cells with Phyllanthus niruri extracts. Huh7.5 cells 
were treated with different concentrations of P. niruri ranging 0.001, 0.01, 0.1, 1, 10, and 100 g/mL, and the number of cells was 
compared to untreated Huh7.5 cells.  A quadratic regression curve was drawn to analyze the change in cells over time. The extracts 




Phyllanthus niruri  Extract 2 does not significantly change the viability of Huh7.5 
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Phyllanthus niruri  Extract 3 does not significantly change the viability of Huh7.5 
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Phyllanthus niruri  Extract 4 does not significantly change the viability of Huh7.5 cells 


































Figure 10a-e.  Change in the number of cells over four day treatment of Huh7.5 cells with Phyllanthus niruri extracts. Huh7.5 cells 
were treated with different concentrations of P. niruri ranging 0.001, 0.01, 0.1, 1, 10, and 100 g/mL, and the number of cells was 
compared to untreated Huh7.5 cells.  A quadratic regression curve was drawn to analyze the change in cells over time. The extracts 





Phyllanthus niruri  Extract 5 does not significantly change the viability of Huh7.5 


































Figure 10a-e.  Change in the number of cells over four day treatment of Huh7.5 cells with Phyllanthus niruri extracts. Huh7.5 cells 
were treated with different concentrations of P. niruri ranging 0.001, 0.01, 0.1, 1, 10, and 100 g/mL, and the number of cells was 
compared to untreated Huh7.5 cells.  A quadratic regression curve was drawn to analyze the change in cells over time. The extracts 
tested included (a) Extract 1, (b) Extract 2, (c) Extract 3, (d) Extract 4, and (e) Extract 5
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Subsection 3: 4.4.3 The effect of P. niruri extracts on J6JFH cells  
For infected cells, treatment with P. niruri extracts results in an increase in the 
number of cells. The results are reported in Figure 11a-c.  This effect was most 
apparent at 24 hours (Figure 11a), where the increase was statistically significant (p < 
0.05) for all concentrations tested for Extract 3 at 0.01 g/mL.  For extract 1, 
increases in concentrations of extract were correlated to an increase in the number of 
cells.  Extract 2 does not seem to vary in its effect on the number of cells over 
concentrations, staying in a narrow range from a 59.9%-73.9% increase in the number 
of cells. Extract 3 varied in its effect over concentrations that neither increases or 
decreases in a particular direction as concentration increased. Extract 4 had the 
strongest effect on the number of cells, ranging from a 96.3% increase in the number 
of cells at 1 g/mL to as much as a 306% increase in the number of cells at 100 
g/mL.  Extract 5 has the second strongest effect, ranging from 87.4-117% increase 
in the number of cells.  The increase was also particularly high for very high extract 
concentrations for Extracts 1 and 4.   It was for this elevation in the number of cells 
that the number of viral copies per cell is used as a means to compare the 
effectiveness of samples to lower viral load, rather than just the viral load alone.  
 At 48 hours (Figure 11b), P. niruri extracts increase the number of cells 
significantly (p < 0.05) in most extracts with some exceptions, notably at 0.01 g/mL 
of Extract 1, 1 g/mL of Extract 2, and 0.001 g/mL in Extract 5. In Extract 3, only 
the lower concentrations of the extract demonstrated a significant effect on cell 
viability, while all concentrations of Extract 4 continued to have strong effects on cell 
proliferation.  For Extracts 1 and 5, the positive effect on cell viability seemed to 
increase with concentration and the effect appeared to plateau at lower 
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concentrations.  The effect in Extract 2, 3, and 4 seemed to decrease as concentrations 
of the extract rises.  The effect in Extract 4 decreases at lower concentrations and 
levels off at concentrations of 0.1 g/mL and greater. Overall, Extract 5 has the 
greatest positive percent increase in cell growth of treated J6JFH infected cells versus 
non-treated cells.  
 Results from 96 hours (Figure 11c) differs from that of 24 and 48 hours. 
Extracts 1, 2, and 3 shows a gradual decrease in percent change between treated and 
untreated cells. Extract 5 data depicts an initial decline in cell viability for lower 
concentrations of 0.001 and 0.01 g/mL and then an increase in cell viability for 
concentrations 0.1, 1, and 10 g/mL. For all extracts, a concentration of 100u g/ml 
results in a significant reduction in cell viability. The largest negative percent change 
belongs to Extract 2 and 3 with values near 77% and 72% decrease respectively. For 
96 hour cells, not many extract samples significantly (p < 0.05) increases number of 
cells in culture. The only samples that have significant p values were Extract 2 at a 
concentration of 10 g/mL and Extract 3 at a concentration of 1 g/mL.  
 Overall, over time, like with the uninfected samples, the effect of extracts on 
cells did not seem to have a negative impact on the number of cells.  In fact, more 
often than not, the number of cells was often significantly greater under the influence 
of the extracts for infected cells, unless the extract was at very high concentrations 
with higher levels of DMSO.  This contrasts with the uninfected cell sample, which 
only saw comparable and occasional increases in cell proliferation.  The increase in 
the number of cells be most easily be seen with Figure 12a-e, which shows the change 
in the number of cells over time due to the effect of different concentrations of a 
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single extract in comparison to untreated infected cells.  Quadratic regression curves 
show that the number of viable cells is either comparable or greater than untreated 





Figure 11a-c: (a) P. niruri extracts significantly (p < 0.05 for all concentrations tested) increase the viability of J6JFH cells after 24 
hours. (b) Extracts result in moderate increase in cell viability for most extracts for 48 hours. (c) Extracts treated 96 hour cells show 
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hours. (b) Extracts result in moderate increase in cell viability for most extracts for 48 hours. (c) Extracts treated 96 hour cells show 




Figure 11a-c: (a) P. niruri extracts significantly (p < 0.05 for all concentrations tested) increase the viability of J6JFH cells after 24 
hours. (b) Extracts result in moderate increase in cell viability for most extracts for 48 hours. (c) Extracts treated 96 hour cells show 



































Figure 12a-e. Change in the number of cells over four day treatment of J6JFH cells with Phyllanthus niruri extracts. J6JFH cells were 
treated with different concentrations of P. niruri ranging 0.001, 0.01, 0.1, 1, 10, and 100 g/mL, or 10 IU/ml of standard interferon, 
and the number of cells was compared to untreated infected J6JFH cells.  A quadratic regression curve was drawn to analyze the 


































Figure 12a-e. Change in the number of cells over four day treatment of J6JFH cells with Phyllanthus niruri extracts. J6JFH cells were 
treated with different concentrations of P. niruri ranging 0.001, 0.01, 0.1, 1, 10, and 100 g/mL, or 10 IU/mL of standard interferon, 
and the number of cells was compared to untreated infected J6JFH cells.  A quadratic regression curve was drawn to analyze the 


































Figure 12a-e. Change in the number of cells over four day treatment of J6JFH cells with Phyllanthus niruri extracts. J6JFH cells were 
treated with different concentrations of P. niruri ranging 0.001, 0.01, 0.1, 1, 10, and 100 g/mL, or 10 IU/ml of standard interferon, 
and the number of cells was compared to untreated infected J6JFH cells.  A quadratic regression curve was drawn to analyze the 



































Figure 12a-e. Change in the number of cells over four day treatment of J6JFH cells with Phyllanthus niruri extracts. J6JFH cells were 
treated with different concentrations of P. niruri ranging 0.001, 0.01, 0.1, 1, 10, and 100 g/mL, or 10 IU/ml of standard interferon, 
and the number of cells was compared to untreated infected J6JFH cells.  A quadratic regression curve was drawn to analyze the 


































Figure 12a-e. Change in the number of cells over four day treatment of J6JFH cells with Phyllanthus niruri extracts. J6JFH cells were 
treated with different concentrations of P. niruri ranging 0.001, 0.01, 0.1, 1, 10, and 100 g/mL, or 10 IU/ml of standard interferon, 
and the number of cells was compared to untreated infected J6JFH cells.  A quadratic regression curve was drawn to analyze the 
change in cells over time. The extracts tested included (a) Extract 1, (b) Extract 2, (c) Extract 3, (d) Extract 4, and (e) Extract 5. 
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Subsection 4: 4.4.4 The effect of P. niruri extracts is still significant with respect to 
the DMSO vehicle control 
 
Based on statistical tests, as outlined in Appendix I, we determined that the 
effect of P. niruri extracts is still significant with respect to the DMSO vehicle 
control.  This was important in order to distinguish if the observed effect was due to 
our extracts or the solvent it was dissolved in.  We looked at the difference between 
the viral copies per cell produce due to our extracts and produced due to DMSO by 
calculating the p-value.  Lower p values mean that the extracts had a significantly 
lower number of viral copies per cell than DMSO.   
  
Subsection 5: 4.5.0 The IC50 and IC90 determined from the cell viability curves at 
each time point  
 
IC50 is the half maximal inhibitory concentration for Extracts 1-5 at three 
time periods of incubation are given in the table below. The lowest IC 50 values 
correspond to Extract 4 at all incubation times. Extract 1 showed a low IC50 value of 
0.95 g/mL for 96 hour incubation. Extract 5 also has low IC50 values for 48 hour 
and 96 hour incubation. Overall, 96 hour incubation requires lower concentration of 
extract to inhibit 50% viral activity compared to 24 hour and 48 hour incubation.  
 IC90 is defined as the concentration of extract needed to inhibit 90% viral 
activity.  A number of our samples did not reach 90% inhibition of viral activity. The 
lowest IC90 concentration corresponds to Extract 2 at 96 hours incubation. Extract 5 
also had a low value, 7.6 g/mL. All other extracts indicated by an IC90 value 
>10g/mL means that the IC90 lies at concentrations higher than the ones tested.  
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Table 5: 50% Inhibitory Concentration (IC50) 
Extract/Time point 24 hours 48 hours 96 hours 
Extract 1 <0.001µg/mL* <0.001µg/mL 0.95 µg/mL 
Extract 2 <0.001µg/mL <0.001µg/mL <0.001µg/mL 
Extract 3 <0.001µg/mL <0.001µg/mL >10 µg/mL** 
Extract 4 0.34 µg/mL, 5 µg/mL 0.1 µg/mL >10 µg/mL 
Extract 5 <0.001µg/mL 0.006 µg/mL 0.6 µg/mL 
* <0.001µg/mL indicates that the IC50 is lower than concentrations tested 
** >10 µg/mL indicates that the IC50 is higher than concentrations tested 
 
Table 6: 90% Inhibitory Concentration (IC90) 
Extract/Time point 24 hours 48 hours 96 hours 
Extract 1 >10 µg/mL* >10 µg/mL >10 µg/mL 
Extract 2 >10 µg/mL 10 µg/mL 0.001 µg/mL 
Extract 3 >10 µg/mL >10 µg/mL >10 µg/mL 
Extract 4 9 µg/mL >10 µg/mL >10 µg/mL 
Extract 5 >10 µg/mL >10 µg/mL 7.6 µg/mL 
* <0.001µg/mL indicates that the IC50 is lower than concentrations tested 





Chapter 5:  Discussion 
 
Section 1: 5.1.0 Plant structure 
Overall our plant proves to be consistent with the general structure associated 
with Euphorbiaceae.  It is hoped that by describing the physical features associated 
with the plant and linking it back to the barcode that it may serve to better identify 
whether P. niruri used in other studies is the same plant.  
 According to the Euphorbia PBI Project, flowers of the Euphorbiaceae family 
are unisexual and simple in structure (Euphorbia Project). The photos of our 
Phyllanthus plants matched these descriptions. We observed both male and female 
flowers, geologically separated on the plant stem. The two sexes of flowers are 
located close in proximity, possibly an evolutionary advantage to ease reproduction. 
Euphorbiaceae family flowers are also characterized by the presence of an involucre, 
base like structure to which both male and female flowers are attached. We did not 
observe an involucre in our magnified photos, however due to the limit of our 
magnification and the small size of all anatomical structures; it is possible we could 
not see some parts of the Phyllanthus plant.  
Flower morphology varies in this family of plants, so it is also possible that 
the involucre is significantly reduced in size or underdeveloped in this species of 
Phyllanthus or just in this particular specimen. The female flowers of the 
Euphorbiaceae family have a pedicel, a three-parted ovary, and are without petals. 
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We observed, on Phyllanthus, that female flowers do indeed have a pedicel attached 
to a three-sectioned ovary (seen in the cross sectional images). Each female flower 
has a three pronged style that each separates into two tips; this is a typical feature of 
female flowers of the Euphorbiaceae family. The male flowers we observed were 
very small and we could not identify all the parts. However, the photos do indicate 
that they are simple flowers, which is again indicative of family Euphorbiaceae.  
 Despite a few minor discrepancies, our photo does provide ample support that 
Phyllanthus niruri falls under the Euphorbiaceae family based on plant morphology, 
specifically an examination of the male and female reproductive organs.  
 
Section 2: 5.2.0 Genetic Barcoding 
Subsection 1: 5.2.1 Our samples are of the same species 
         DNA barcoding shows Phyllanthus niruri and Phyllanthus amarus can be 
successfully distinguished from other Phyllanthus species with rbcL and matK 
regions.  There were 5 segregating sites observed during matK alignment where were 
not significant during mapping. Moreover, no segregating sites were observed for 
rbcL alignment. In both mapping approaches, the closest matches were P. niruri, P. 
amarus, or either.  Our data suggests that all of our samples are of the same species. 
The closest neighbors that showed slight similarity to our samples were P. 
tenellus and P. nummulariifolius.  These neighbors were observed in both matK and 
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rbcL mappings.  However, they were only seen through the tree-based method and 
not the distance based method. 
 
Subsection 2: 5.2.2. Our samples are P. niruri and P. amarus 
Distance-based mapping for rbcL showed significant matches between our 
samples and P. niruri voucher.  The next closest match of P. amarus only has 83% 
coverage compared to 92% coverage with P. niruri rbcL gene.  Furthermore, the P. 
amarus hit only scored 894 compared to 985 from P. niruri.  There is a significant 
drop off in score following the best match of P. niruri.  This suggests that all of our 
samples are likely to be P. niruri. 
Distance-based mapping for matK showed significant matches between our 
samples and P. amarus matK gene.  The next two closest hits are both from P. 
amarus with similar max scores of 1515 and 1509 respectively compared to the best 
hit score of 1515.  The top three hits have 96% query coverage and 99% max 
identity.  P. niruri genes did not return as hits through default settings of BLAST. 
This suggests that our plant may be P. amarus as well as P. niruri. It is likely that 
since these two species have been so taxonomically confused in the past, researchers 







Section 3: 5.3.0 HPLC analysis of data 
The HPLC data indicates that the composition of the extracts varied widely 
between the fractions (Table 4a-b). This indicates that the chemical composition 
between fractions is likely similarly varied. However, there were a few anomalies in 
the overall data. To begin, extract 2, which was the hexane partition had a large peak 
around 8 that was absent from fraction one. This is unusual, due to the fact that all 
peaks in fractions 2-5 should be contained in some capacity in fraction one. This peak 
was not located anywhere in fraction one. Other deviation in specific retention times 
is more explainable by the fact that increased or decreased separation can be seen 
depending on the total composition of the fraction, but an entirely new peak was 
surprising to see. This could indicate that some sort of decomposition or reaction 
went on in this fraction to account for the appearance of a new peak. 
         Also, initially when we ran the HPLC we injected the fractions in pure DMSO 
at 50:50 ACN:water and saw no separation. Thus we lowered the acetonitrile 
concentration to 25%. This gave use slightly better separation, but we realized it was 
likely the increased amount of DMSO that was detrimentally affecting the separation. 
Thus we diluted our samples into water. This significantly increased the separation, 
but lead to broad peaks due to the now high solvent polarity. Ideally, we would re-run 
the samples in water with the original 50:50 acetonitrile:water solvent ratio. 
         In addition, the GCMS data unfortunately was not as useful as we thought it 
would be. The boiling points of the compounds in the extracts are simply too high to 
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allow evaluation through GCMS. Instead, a procedure such as LCMS would lead to 
the best method for analysis. Also, it may be useful to instead use a soft ionization 
method like electrospray ionization to prevent fragmentation and then comparing the 
molecular ion masses to a table of known phytochemical compounds in P. niruri. 
 
Section 4: 5.4.0 The effect of P. niruri extracts on HCV viral copies per cell shows 
different kinetics across the time points 
 
 Overall, P. niruri extracts have a significant potent effect on HCV viral 
copies per cell, as compared to the effects of interferon alpha.  Different extracts 
exhibit varying activities across the time points which indicate different metabolic 
stabilities and suggesting possible different mechanisms of action. Each of the 
extracts exhibits varying kinetics over time, suggesting different mechanisms of 
action in addition to different metabolic stability in vitro.  
The initial methanolic extract, labeled extract 1, maintained a relatively high 
level of viral suppression at the lowest concentration of 0.001 g/mL maintaining 
viral suppression between 62.7%-79.4% over the full course of the study from 24 
hours to 96 hours (Figures 8a,c).  This indicates that the effect of the extract is 
prolonged, likely due to greater stability which allows the concentration in vitro to 
remain above active levels.  
Viral suppression in hexane fraction, Extract 2, was similarly maintained from 
24 to 96 hours staying between 67.0-88.5% even at the lowest concentration of 0.001 
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g/mL (Figures 8a,c. Similar to Extract 1, this indicates that there is a strong and 
immediate suppression of the HCV viral load which is not changed, and if anything 
seems to increase, over time. This likely means that the active compounds found in 
extracts 1 and 2 are not degraded below their active concentrations over time. This is 
an important factor to take into consideration with future studies as compounds which 
are degraded in vitro may be even more quickly when moved into in vivo models.  
In contrast, the CCl4 layer, extract 3, did not experience maintenance of 
activity over the course of the study. Even at the ten-fold higher concentration of 1 
g/mL, the viral load suppression dropped from 70% suppression at 24 hours to 
30.4% at 96 hours (Figures 8a,c). While this initial level of suppression was 
comparable to the level of suppression seen in the 0.001 g/mL concentrations of 
both extracts 1 and 2, it is clear that they do not follow the same time course of 
activity. The most likely explanation for this is simply that the active compounds in 
extract 4 are not metabolically stable in this system. It may be helpful to determine 
the time point at which this extract has maximal activity through a more intensive 
time course study over the first 24-36 hours to track the activity. However, while this 
decrease in activity over time is not ideal, it can be compensated for in vivo through 
more frequent administration of doses. 
More dramatically, the final methanolic fraction, extract 4, dropped from the 
near total suppression of viral load of 99.4% at 24 hours to 42.4% suppression at 94 
hours for the largest tested concentration of 10 g/mL (Figures 8a,c). Again, this very 
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high antiviral activity, which was found for these compounds at the highest tested 
concentration, was not sustained for the full time course. This means that they start 
off with strong antiviral effects that are not sustained across the full 96 hrs. Again, 
this may simply be an indication that the compound is metabolisms in the medium 
below its active concentration.  However, there may also be additional mechanistic 
effects at play. The inhibitory compounds may be acting later in the viral replication 
cycle, such as inhibiting the release of mature virions to immediately cause the strong 
decrease in viral load or deactivate HCV virions before they can infect the cell. 
However, this effect may not be maintained over time as the compounds degrade.  
 Finally, the chloroform extract indicated that a reversal of the type of viral 
suppression found in extracts 3 and 4 at its highest concentration of 10 g/mL. 
Extract 5 (at 10 g/mL) actually started with a low level of viral suppression of 8% at 
24 hours which increase drastically to near fully suppression of 99% at 96 hours 
(Figures 8a,c). This indicates a very interesting mechanism in which the anti-viral 
activity is more long term. More interestingly, this was comparable to the effect of 
interferon-alpha at 10 IU/mL which also started with low suppression of 12.1% at 24 
hours that increase to 93.7% suppression at 96 hours. Even though extract 5 dose take 
a longer time to work, it does result in a viral suppression level equivalent if not 
higher than that of the currently approve treatment with interferon.  
 One part of the data that we did not expect to see with extract 5 was seen in 
Figure 8a, which shows the change in viral RNA suppression over concentration of 
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extract at 24 hours.  Extract 5 does not seem to have a predictable pattern over 
concentration, and jumps rather erratically from a possible strong 80% increase in 
viral to a 50% decrease in viral load and then back down to no change in viral load 
compared to control.  This time point most likely needs to be repeated.  
This may suggest that the extract may be interfering with another process of 
HCV viral replication that is delayed, such as inhibiting integrase, reverse 
transcriptase, or protease. The HCV RNA genome consists of a single stranded RNA 
molecule (~9600 nucleotides) which encodes proteins crucial to the replication of 
HCV (Ravikumar et al., 2011).  These include some structural proteins and the 
nonstructural proteins: NS2, NS3, NS4A, NS4B, and NS5B (Bartenschlager, 2005).  
As NS2 and NS3 in particular play a critical role in HCV replication, inhibiting their 
function would greatly suppress viral load in HCV-infected cells.  Ravikumar et al. 
(2011) investigated the effect of P. amarus root and leaf extracts on NS3 protease and 
NS5B RNA dependent RNA polymerase, and found that there was significant 
inhibition.  NS3 was inhibited more by the root extract, while HS5B was inhibited 
more by the leaf extract.  Addition of root extract with interferon alpha showed an 
additive effect in the inhibition of HS5B. 
 
Subsection 1: 5.4.1 P. niruri does not have a significant effect on cell toxicity in 
uninfected Huh 7.5 cells and does not display an inhibitory effect on J6JFH cells 
 
Our results indicate that P. niruri extracts exhibit little toxicity on uninfected 
Huh 7.5 cells and infected J6JFH cells, the liver cancer cells used as a model for 
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HCV infection.  In the 48 hours and 96 hours of the assay, there was little impact on 
cell number, suggesting that extracts are nontoxic at the concentrations tested.  The 
only toxicity seen was at 100 g/mL concentrations of the extracts at 96 hours, which 
is likely due to the fact that the DMSO concentrations were too high at 2.5%.   
Concentrations this high were also not used to test the effect of the extract on the viral 
load, and are also not clinically applicable.   
One limitation we had is that some particular samples did not show an 
absorbance value, and were calculated to have a negative cell number of cell number 
close to zero, such as in Figure 10c and 10e.  However, it is not likely that the extracts 
were toxic, since the number of cells in later time points for the same treatment 
condition was very high, but perhaps that the cells were not seeded probably. 
Moreover, the concentrations that we tested were pharmaceutically viable and 
also led to a suppression of viral load.  Our concentrations were well within the range 
of concentrations cited in the literature.  Ravikumar et al. (2011) treated Huh7 cells 
with P. amarus leaf and root extracts at concentrations up to 250µg/mL, and no toxic 
effects were found.  As our maximum concentration (10 g/mL) was well below the 
concentrations that Ravikumar et al. (2011) used, we can infer that our experimental 
design would not induce hepatotoxicity. 
This result is a positive indication for the overall success of this cell model, 
and is further supplemented by a study conducted by Lee, Jagannath, Wang, & 
Sekaran (2011).  This group found an anti-metastatic effect of Phyllanthus extracts on 
A549 human lung and MCF-7 breast cancer cell lines. Extracts of four Phyllanthus 
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species (P. niruri, P. urinaria, P. watsonii, and P. amarus) were used and they 
reported IC50 values ranging from 50 - 180 µg/mL for methanolic extracts and 65 - 
470 µg/mL for aqueous extracts.  It was shown that Phyllanthus was capable of 
inducing apoptosis in conjunction with anti-metastatic effect due possibly to 
polyphenols present in its extracts (Lee, Jagannath, Wang, & Sekaran, 2011). 
However, this could have proven to be difficult for our model, since it utilizes 
liver cancer cells in order to get a sustainably infective cell line to mimic in vitro 
HCV infection.  However, since this anti-cancer activity was found in lung cancer 
cells, it is likely that it would exhibit a different oncogenic pathway from the Huh7.5 
liver cancer cells utilized in this study.  While this also does not eliminate the 
potential of P. niruri as a cancer therapeutic, it does allow continued use of the 
Huh7.5 as a proper model for in vitro HCV infection without worry of masking the 
anti-viral or cell survival effects of the HCV infected cells due to the killing of the 
cancer cells. 
Although the origin of the proliferative activity observed by some extracts on 
the J6JFH cells remains unclear, they may lie in the consideration of direct anti-viral 
activity.  Previous literature offers some insight into these mechanisms, though not 
specifically for HCV-infected cell lines. For example Qian-Cutrone et al. (1996) 
showed viral replication inhibition of HIV through the action of niruriside.  Niruriside 
inhibited reverse-transcriptase, the key enzyme used to synthesize DNA from an 
RNA template. Moreover, Venkateswaran, Millman, and Blumberg proved as early 
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as 1987 that P. niruri had the ability to inhibit DNA polymerase in Woodchuck 
hepatitis virus (WBV) and HBV. 
While these results indicate that the extracts are not toxic to the liver cancer 
cells (as shown by the absence of toxicity to the cell line), they may in fact have a 
hepatoprotective effect, a finding reported by Sarkar and Sil (2007).  Sarkar and Sil 
(2007) investigated the hepatoprotective role of P. niruri protein isolates against 
thioacetamide.  Thioacetamide is metabolized into thioacetamide sulfoxide, a ROS 
responsible for the degradation of biomembranes and DNA that subsequently leads to 
cell death.  Pretreatment reduced the production of malodialdehyde (MDA), an 
indicator of reduced oxidative stress in cells.  Treatment with protein isolate alone 
(without treatment with thioacetamide), did not result in an increase in MDA levels, 
suggesting that P. niruri has a protective effect rather than a restorative effect against 
ROS induced cell toxicity.  Since the viral infection through HCV can cause 
significant oxidative stress on the tissue and cells, it may be that P. niruri could 
promote cell proliferation through a protective process. 
However, these studies also do not fully answer questions about more global 
toxicity in-vivo.  Manjrekar et al. (2008) reported the formation of dense eosinophilic 
casts in the kidneys and testes of rats that were treated with P. niruri.  These casts 
were dense protein masses that could lead to kidney failure and infertility (Manjrekar 
et al., 2008). While this is relatively new and surprising data given the wide spread 
use of this plant for various ailments including urinary problems (Patel, Tripathi, 
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Sharro, Chauhan, & Dixit, 2011), it does indicate that there may potentially be other 
toxic effects to the plant which should be studied more in depth before these extracts 
are considered for human trials. 
Subsection 2: 5.4.2 IC50 and IC90 values reveal effectiveness of extracts 1-5 as a 
dose dependent response on the inhibition of viral copies per cell 
 
IC50 and IC90 are measurements of drug effectiveness. The value for IC50 
(Table 5) is the concentration of extract needed to inhibit 50% of viral activity in vitro 
while IC90 (Table 6) is concentration required for 90% inhibition. Tables 5 and 6 are 
repeated below for the ease of interpretation. 
Table 5: 50% Inhibitory Concentration (IC50) 
Extract/Time point 24 hours 48 hours 96 hours 
Extract 1 <0.001g/mL <0.001g/mL 0.95 g/mL 
Extract 2 <0.001g/mL <0.001g/mL <0.001g/mL 
Extract 3 <0.001g/mL <0.001g/mL >10 g/mL 
Extract 4 0.34 g/mL, 5 g/mL 0.1 g/mL >10 g/mL 
Extract 5 <0.001g/mL 0.006 g/mL 0.6 g/mL 
 
Table 6: 90% Inhibitory Concentration (IC90) 
Extract/Time point 24 hours 48 hours 96 hours 
Extract 1 >10 g/mL >10 g/mL >10 g/mL 
Extract 2 >10 g/mL 10 g/mL 0.001 g/mL 
Extract 3 >10 g/mL >10 g/mL >10 g/mL 
Extract 4 9 g/mL >10 g/mL >10 g/mL 
Extract 5 >10 g/mL >10 g/mL 7.6 g/mL 
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More effective drugs have lower IC values because lower concentrations are 
needed to achieve a certain level of viral inhibition. While it is possible to get 
increased activity with higher dose of drugs, this is not ideal due to the increase of 
negative side effects. A high concentration is neither ideal nor probable for drugs 
because it is much more likely that high doses would be detrimental to cells. In 
addition, high concentration of extracts would require larger amounts of DMSO, 
which may be toxic to cells at high concentrations thus masking any anti-viral effects 
or cell rescuing effects. In addition, the higher concentrations indicate amounts that 
would never be feasible in actual pharmacological studies, as it would not be possible 
to get a dose that large systemically in an in vivo model. 
Each set of time points showed variability in the IC50 values. As discussed in 
section 5.4.1, extracts 1 and 2 have sustained activity across the three time points, 
while 3 and 4 decrease over time and 5 and six increase over time. In our data of 
IC50 values for 24, 48, and 96 hours incubation, we expect the less concentration of 
extracts for longer incubation times because the extract has had more time to affect 
viral activity. Most of the compounds have an IC50 that is lower than the actual 
tested concentrations. This indicates that in order to find the true IC50 value it would 
be necessary to test lower dilutions of the compound. 
This is supported by our data as all extracts with the exception of extract 2 
have significantly lower IC50 concentrations compared to 24 and 48 hour times. 
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Extracts 4 and 5 were also very effective at 48 hour incubation, which could indicate 
that these two extracts are more potent than extracts 1 and 3. 
IC90 values indicate drugs are effective enough to reduce viral activity by 
90%. Many of our samples did not reach this percentage of viral inhibition, and thus 
their IC90 concentrations are probably higher than the values that we tested. Out of 
the 5 extracts, only extract 2 had a significantly low IC90 value for 96 hour 
incubation time. We would expect low IC90 values to occur at longer incubation 
times for the same reason as for IC50. It is not unexpected that many samples did not 
have an IC90 value because the IC50 values were not all significant thus we predicted 
that the extracts would not be able to inhibit viral activity much above 50%.    It was 
also not expected to see such a large difference between the IC50 and the IC90 
values.  However, the mechanistic and metabolic stability of the compounds will play 
a large role in the actual IC50 and IC90 dependence over time. This may be altered 
by repeated treatment of the cells at multiple time points.  
 
Subsection 3: 5.4.3 Connections to HPLC Data  
 Our most active extracts based on the cell data were extracts 4 (24 hrs) with 
an IC50 of 0.34 g/mL and extract 5 (96 hrs) with an IC50 of 0.6 g/mL. However, 
extract 4 did not have long term sustained activity, despite the fact that it was one of 
the only extracts able to reach almost complete viral load suppression. In contrast, 
extract 5, which also had near total viral suppression at 96 hours, had very low 
activity at 24 hours. 
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Extract 4 is the residual methanolic extract after having been partitioned with 
hexane, CCl4, and CHCl3. Extract 5 is the final chloroform partition. These two 
extracts were also assumed to contain the largest amount of niruriside which 
functions to inhibit HIV reverse transcriptase activity (Qian-Cutrone et al., 1996). 
Based on the HPLC data these two extracts share peaks in common at around 2.6 
minutes and 2.8 minutes, which were detected by both the 280 nm and 254 nm 
detectors. In addition, at around 3.0 minutes there was a peak found only in extracts 
4, 5  and 1 (which was the original extract thereby containing all peaks.)  
 These results may indicate that some of the HCV active compounds are 
localized in the methanolic and chloroform fractions. These fractions may be an ideal 
place to begin future studies into the identification of active compounds. Previous 
literature studies indicate that the methanolic extracts may contain active compounds 
(Qian-Cutrone et al., 1996). In addition, Ravikumar et al. (2011) indicate potential 
compounds which are found in these species of Phyllanthus. It is possible that one or 









Chapter 6:  Conclusion 
 
P. niruri is a historic medicinal plant best known for applications ranging 
from the treatment of kidney stones to the protection of liver cells from toxins. This 
study sets out to explore the therapeutic potential of P. niruri in the treatment of 
hepatitis C viral infection, which specifically targets the liver. This project was 
approached through a three-part methodology. The methodology consisted of genetic 
barcoding of individual plant samples, chemical extraction of those plants, and cell 
culture studies using the obtained extracts. The preliminary results of the plant extract 
efficacy on HCV infected cell viability and HCV viral load suppression were 
measured and analyzed. These were then accompanied by a genetic barcode record to 
indicate the consistency of the plant species among the chosen specimens. 
The extraction protocol resulted in five chemically unique extracts, whose 
basic profiles were analyzed using HPLC. These extracts were chosen with support 
from literature to provide the greatest chance of obtaining an active fraction. While 
they do not represent the only valid and active extractions seen in the literature, they 
provided a set of unique extracts whose activity could be tracked through the various 
partitions. In addition, the HPLC profile provided a general outline for the 
distribution of potentially active compounds across the extractions. Even so, more 
research may be necessitated into furthering and refining the HPLC profiles and 
potentially looking into the actual active compounds which may already have been 
identified in the literature. 
To determine the efficacy of P. niruri as an HCV antagonist five 
concentrations, ranging from 0.001g/mL to 100g/mL, of each extract were each 
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tested individually for their ability to suppress HCV viral load and improve cell 
viability in the infected cell line Huh 7.5. Analysis showed that all of the extracts 
increased cell viability significantly, ranging from 36.9% to 138.7% for infected cells 
at 24 hours and 19.9% to 147.9% at 48 hours. The effect seems to decline at 96 hours, 
where the effect ranges from a 20% drop in viability to an 40.6% increase. 
Additionally, little to no change in viability was observed on the uninfected control 
cell line when exposed to each of the extracts. This supports the idea that these P. 
niruri extracts contain active compounds that directly or indirectly diminish HCV’s 
ability to infect and kill the cells, as opposed to causing an inherent proliferation of all 
liver cancer cells of this type.  
In addition, the viral suppression results were equally promising. One of the 
five extracts, Extract 5, produced greater HCV viral suppression over a four day 
period than standard interferon, one of the few current treatments approved by the 
FDA for HCV infection. Two other extracts, 3 and 4, showed strong initial 
suppression in the first 24 hours, but around 50% of this suppression was sustained 
over the entire  four day period. Of the two extracts that surpassed standard interferon 
alpha, extract 4 showed a maximum efficacy at 10 g/mL with 99.4% suppression at 
24 hours while 5 had its maximum efficacy at 10g/mL with 99% suppression at 96 
hours all of which are considered viable concentrations for clinical use.   
The results of the genetic barcoding using the matK and rbcL chloroplast 
regions indicated that all of the specimens extracted and subsequently tested in cell 
culture were the same species. Furthermore, the results indicated that the plants tested 
are most likely Phyllanthus niruri, and that the closest relative is Phyllanthus amarus.  
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In future studies specimens used for experimentation should be harvested from a 
single lineage of plants descended from a single original plant.  This will eliminate 
the need to verify that all of the specimens used are from the same species. 
This study highlights the need for further research on the potential 
applications of P. niruri in treating HCV. The results of this study themselves are 
limited in their scope, and do not delineate a mechanism for the increased viability or 
viral suppression observed. The exact method through which this activity is obtained 
is not directly clear through our research. Whether this proliferative effect is a result 
of anti-oxidant effects, or the direct inhibition of viral replication, or even prevention 
of viral entry into the cells is still unclear and mandates further research. Moreover, 
they do not suggest which compounds within the extracts are responsible for the 
associated effects, or whether it is a combination of compounds responsible. Yet, 
these preliminary results are important in establishing a motive for further, more in-
depth research into this plant’s phytochemicals and their medicinal properties, 
especially against HCV. 
Further studies should be completed which confirm whether or not the cell 
viral load matches that with the supernatant.  It would also be valid to examine any 
synergistic effects seen when combining the extracts with one another, or with 
standard interferon-alpha itself or qualitative studies should be used to identify 
possible active compounds within each extract responsible for the anti-HCV effects. 
Many of these compounds may have been previously identified in the literature, thus 
it may be necessary to only isolate the compound as opposed to doing a thorough 
structural identification through HPLC or Mass Spectrometry. Additionally, any 
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identified active compounds should then be studied in association with HCV to 
determine the mechanism by which the HCV virus replication or viability is hindered. 
Finally, we recommend studies that manipulate the conditions presented in this study, 
such as the solvent used to dissolve the extract, in order to determine factors that may 


















Appendix A: Plant Care 
In total, we have three sets of plants grown and harvested under specific conditions. 
1. Set 1 (A1-50, B1-5, C1-3) 
a. Planting 
i.The US Botanic Garden (USBG) offered to help grow the plant 
with seeds obtained from an online retailer, Trade Winds Fruit 
(http://www.tradewindsfruit.com/).  The plants were 
germinated on March 23, 2010 +/- 10 days.   
b. Growing conditions 
i.The plants were grown at the US Botanic Garden Greenhouse. 
c. Harvest and Drying Conditions 
i.On day 96 (June 26, 2010), the plants were harvested. The plants 
were air dried for 10 days, in the dark, under 60-70% humidity, 
at a temperature of 18C-22C. 
2. Set 2 (A 100 - 199, B1-5, C1-3) 
a. Harvesting and Drying Conditions 
i.On day 179 (September 17, 2010), the plants were harvested from 
the USBG Greenhouse. The plants were air dried for 20 days 
(?), in the dark, under 50% humidity, at a temperature of 15.5C 
- 18.3C. 
3. Set 3 (A200-299, B1-5, C1-3) 
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a. Growing conditions 
i.On Day 181 (9/20/10), the plants were moved to greenhouse lab 
space at the University of Maryland College-Park, graciously 
offered by Dr. Betty Morgavan, the research greenhouse 
complex director and manager.  We were also informed that 
spider mites grow on our plant. 
ii.On Day 352 (3/10/11), we noticed that the plants didn’t look very 
healthy.  The leaves and stems were yellowing and the leaves 
were always closed up on the flowers, rather than opened up as 
we had seen in the US Botanic Garden.  After consulting with 
experts at the US Botanic Garden and Dr. Morgavan, we 
realized that salts had been building up in the soil of the plants 
so we replaced the soil.  After the soil change, the plants 
looked more healthy, fresh, and green.  This soil contained 4 
parts PX1 (a bark based soilless soil) to 1 part gran-i-grit 
(crushed granite). 
iii.On Day 380 (4/7/11), we noticed that we have West Florida thrips 
growing on our plant.  In 8 samples (one branch size of 2-3 
inches) taken, we found 1 thrip per sample on 2 samples. 
iv.On Day 395 (4/22/11), we noticed that the plants grow in the 
presence of fungus gnats, which come around when the soil is 
wet, as they like to lay their eggs in wet soil and their larvae 
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cannot exist unless the soil is wet.  This usually occurs when 
seeds are planted due to the soil having to stay wet for 
germination.  The damage from fungus gnats comes from the 
larvae chewing on roots of very young plants, which is not a a 
problem with your plants according to the Greenhouse 
Director, Dr. Morgavan. 
v.Periodically during the growing period, we re-potted many plants 
so that their growth wouldn’t be stunted by their pot and lack 
of nutrients 
b. Harvesting and Drying Conditions 
i.This set of plants were grown under greenhouse conditions were 
harvested on Day 345 (3/3/11). 
ii.The plants were air dried for 7 days, in the dark, at ~40% humidity, 
and at 18C +/- 2C.  Plants were dry to the touch after day 4, but 
were left until day 7 then harvested into Ziplock bags.  Each 
plant was bundled with a rubber band and hung upside down in 
a basement room. Plants were not exposed to sunlight nor light 
of any kind. The humidity was 40% and remained consistent 
throughout the drying period.   
Greenhouse conditions 




a. In the greenhouse, the curtains close when it is too hot or if the sun 
level too high, detecting the light intensity in the form of foot candles 
(fc) 
b. If it is cool outside and not as sunny, then the shades will open. 
c. If it is too hot or too sunny, the shades will close all the way. 
2. Temperature and Humidity 
a. The greenhouse is maintained at 26*C and 50% humidity. 
3. Watering 
a. Medium watering worked best, and greenhouse staff watered the 
plants when needed.  Some that were root-bound that dried up very 
quickly. 
4. Soil 
a. The plants need gravely and lime soil.  However, the plants are 
growing on LC1 soil, which is a peat base, soil-less soil with no 
organic matter, so it doesn’t hold fertilizer.  This type of soil is hard to 
over-fertilize and once the soil is dried out, it is very difficult to re-wet 
the soil.  Heavier soil types tend to hold more water.  This type of soil 
also results in soil compaction, which stresses the plants and caused 
pink tinge on leaves to appear.  The plants were not fertilized.   
5. Lights 
a. The greenhouse is set to maintain the light range between 10 -30 fc.   
In addition, the shade curtains will close when the outside light foot 
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candles gets above 35 foot candles OR the outside temperature gets 
above 30C.   
b. The lights were HID lights, which turn on at 6 AM and off at 8 PM, if 
it is not too sunny. 
c. If the sun is below 10 foot candles (i.e. cloudy), the light will be on. 
d. If the sun is too bright at 30 foot candles, light turns off 
Appendix B: DNA extraction protocol 
 (Qiagen, 2006) 
DNA extractions were performed on 20 mg dry samples using the DNeasy Plant Mini 
Kit (Qiagen, 2006). Prior to extraction the samples were lysed using the TissueLyser 
System (Qiagen) with glass beads. Extraction proceeded following the 
manufactureres protocol. 
 
Appendix C: PCR Protocol 
 (Fermentas Life Sciences, 2007), (Ottesen, personal communication, October 2009) 
 
Make sure that the preparation of the PCR mixture is done over ice. The quantity of 
each component depends on how many PCR reactions we will be setting up. We will 




Master-mix                                 3.0µl 
10mM dNTP’s                                  0.8µl 
100 µM Forward Primer                   0.1µl  
100µM Reverse Primer                     0.1µl 
Bioline Biolase taq (5U/µl)    0.2µl 
DNA                                                  1.0µl 
H2O                                        14.8µl 
 
After all components are assembled, gently vortex the sample and briefly centrifuge 
to collect all drops from walls of tube. Place the mixture in the thermocycler which 
will start the amplification process at 95°C for 3 min. Then proceed at 94°C for 30 
sec, 55°C for 1 min, and finally 72°C for 1 min. This cycle will be repeated 5 times.  
Then the reaction will go back up to 94°C for 30 sec, 54°C for 30 min, and finally 
72°C for 1 min with a final extension of 10 minutes at 72°C. The reaction will hold at 
10°C until we are ready to take out the PCR product. 
 
For matK PCR, 40 cycles instead of 30 cycles will be used at an annealing 




Appendix D: Basic cell maintenance (Zhang, personal communication, June 2009) 
The purpose for basic cell maintenance is to keep up a cell line to allow for optimal 
cell survival. 
For HIV cell culture system for HIV, a proper media must be made in which cell will 
grow. To make the B-cell media, combine 435 mL RPMI, 50 mL 10% FBS, 5 mL 1% 
Pen/Strep, and 10 mL 2% Glutamine. HIV infects white blood cells, which do not 
replicate; they are produced by the body.  Thus, new cells must be acquired for each 
assay. 
 
For J6JFH cell culture system for HCV, a proper media must be made to allow for 
optimal cell survival.  To make the hepatitis C media, add 445 mL DMEM, 50 mL 
FBS, and 5 mL Penicillin/Streptomycin. 
 
Protocol for splitting liver cancer cells (Zhang, personal communication, June 
2009) 
Cells must be split because over time, the cells will grow to the capacity of the plate 
and have no place else to grow.  At that point, the cells will begin to die. 
1. Filter medium and trypsin to remove any contaminating bacteria and viruses 
in the media.  The filter has 0.2 micron pores. 
2. Add 10-12 mL medium to each flask that the cells will be split into. 
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3. Label each flask with the passage number (number of times the cell line has 
been split), desired split ratio i.e. 1:4 ratio from the original stock, name of the 
cell line, and date 
4. Aspirate out medium from original stock. 
5. Add 2 mL of trypsin to wash the cell ask to remove any dead cells. 
6. Aspirate out the 2 mL of trypsin. 
7. Add another 2 mL of trypsin to detach the cells from the bottom of the flask 
8. Cap the flask and tip the flask back and forth to evenly distribute the trypsin 
9. Incubate the flask at 37°C for 2 minutes 
10. Take the flask out and tap the flask on the side.  It should be visible whether 
or not the cells have detached from the flask walls. 
11. Add 4 mL of medium and resuspend the cells well with a pipette.  Add the 
appropriate amount of cells to each flask and place in the 37°C incubator until 
needed.  For example, given that the total volume of trypsin and medium at 
this step is 6 mL, and the desired splits are 1:3, 1:3, 1:6, and 1:8, aliquots 
would be as follows: 1:3 flask will have 2 mL of the original cell stock; 1:3 
flask will have 2 mL of the original cell stock; 1:6 flask will have 1 mL of the 






Appendix E:Materials for cell culture 
Laboratory space in NIH 
Dr. Shyam Kottilil has graciously allowed us to conduct our studies in his lab at NIH.   
 
The laboratory is equipped with basic laboratory tools and specific machines such as: 
 Applied Biosystems Real-time PCR 7500 machine and software 
 Millipore Guava ViaCount Cell Viability machine and software 
 Guava instrument cleaning solution (ICF) 
 Guava ViaCount Reagent 
Reagents 
 1% FBS (Fetal Bovine Serum albumin) 
 Penicillin/Streptomycin antibiotics 
 Recombinant human interferon alpha 2 (Hu-IFN-2; Hu-IFN-2b) 
 T-20 (HIV conventional treatment) 
 RPMI Medium 1640 1x 
 Glutamine 
 DMEM Medium 
 Trypsin 
 98-100% Ethanol 
 J6JFH-2a virus standard 
 J6JFH-2a virus probe 




Kits and cell lines 
 Cell lines which can be obtained at NIH 
 J6JFH HCV cell culture cells 
 MDM (monocyte-derived macrophages) HIV cell culture cells 
 Ambion RNAqueous - 4PCR Kit 
 Qiagen Viral RNA Extraction Kit 
 96-well optical reaction plates for PCR 
 MiccroAmp, Optical 8-cap strip 
 
Appendix F: Viral RNA extraction 
Viral RNA will be extracted from the cell supernatent.  The volume for ethanol, 
supernatant sample volume, and buffer was tripled in order to obtain a high enough 
viral RNA concentration. 
Follow the manufacturer’s instructions for QIAamp Viral RNA Mini kit (Qiagen, 
2010).   
Appendix G: HPLC Protocol (Markom, Hasan, Daud, Singh, & Jahim, 2007), 
(Murugaiyah & Chan, 2007b) 
 
1. If our most active compounds end up to come from the less polar solvent 
extracts, we would likely want a C4 column* or C8 at the most, where as 




2. The most consistent size for natural product analytical HPLC was 250 mm ! 
4.6 mm i.d. and 4 µm particle diameter. 
3. 1-2 µg of purified extract can be dissolved either in DMSO or a comparable 
non-reactive solvent (such as acetonitrile) so that no particulates remain then 
20 µL will be injected into the column.  You do not want the injected volume 
to be too concentrated otherwise you risk clogging the highly expensive 
column. 
4. The column will then run with a gradient of two solvents with 0.1% HPLC 
grade Trifluro acetic acid (TFA), which improves the peak shape. 
5. We will run an isotonic gradient of acetonitrile (B) and water (A), at around 
25:75 volume ratio over a 10 minute period. The flow rate should be held 
constant at 0.5-1.0 mL/min. 
6. As the parts are separated on the column, they will pass through a UV detector 
at the end. There are two ways to collect spectra depending on the lamp 
available to you, at a set wavelength, in which 254 nm and 280 nm would be 
the most efficient one for optimal absorbance of most compounds. The second 
choice would be to collect PDA spectra, which shows the intensity and 
amount of absorbance of what is passing the detector across all of the 
wavelengths it can detect. While the PDA spectra does give far more 




Appendix H: Real-time PCR reaction components (Applied Biosystems, 2010) 
Master mix prep for samples 1 reaction 
2x Master mix 12.5 µl 
40x RNase inhibitor 0.625 µl 
3.2 nM forward primer 1.25 µl 
3.2 nM reverse primer 1.25 µl 
2.5 nm probe 1 µl 
Water 0.375 µl 
Sample 25 µl 
 
 
Standard samples 1 reaction 
2x Master mix 12.5 µl 
40x RNase inhibitor 0.625 µl 
3.2 nM forward primer 1.25 µl 
3.2 nM reverse primer 1.25 µl 
2.5 nm probe 1 µl 
Water 3.375 µl 
Standard sample 5 µl 
Total 20 µl 
 
 
After loading the plate into the PCR machine, use follow PCR conditions to run the 
assay: Hold for 30 minutes at 48°C. Hold for 10 minutes at 95°C. Run 40 cycles; 
during one cycle, denaturing of the RNA will occur at 95°C for 15 seconds and 
annealing will occur at 60°C for 1 minute. 
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Appendix I: P-values: p-values for significant differences between viral copies 
per cell rates in P. niruri extracts and DMSO vehicle control at 24 hours (a), 48 
hours (b), and 96 hours (c). 
Table 7a 
Concentration Extract 1 Extract 2 Extract 3 Extract 4  Extract 5 
0.001 g/mL 0.032515 0.129655 0.018673 0.054401 0.275389 
0.01 g/mL 0.049336 0.048443 0.059523 0.009211 0.441174 
0.1 g/mL 0.001672 0.492549 0.035099 0.001803 0.000477 
1 g/mL 0.014218 0.868622 0.610586 0.209952 0.012689 
10 g/mL  0.015148 0.019641 0.040052 0.001511 0.012548 
 
Table 7b 
 Extract 1  Extract 2 Extract 3 Extract 4 Extract 5 
0.001 g/mL 0.214168 0.050031 0.355779 0.625189 0.00144 
0.01 g/mL 0.48885 0.105866 0.349787 0.022063 0.025158 
0.1 g/mL 0.080976 0.595292 0.324903 0.025015 0.33275 
1 g/mL 0.013046 0.837104 0.34127 0.032028 0.033256 







 Extract 1  Extract 2 Extract 3 Extract 4 Extract 5 
0.001 g/mL 0.013329 0.004465 0.014136 0.211342 0.029411 
0.01 g/mL 0.045416 0.37786 0.039387 0.343234 0.814709 
0.1 g/mL 0.089056 0.006538 0.062638 0.337574 0.074147 
1 g/mL 0.488162 0.034517 0.202324 0.007149 0.003391 
10 g/mL 0.099404 0.248611 0.528244 0.001034 0.002403 
 
Appendix J: Time-course treatment schedule: Time-course treatment schedule 
The following is a schedule of the time scale treatment. Our cell samples will be 
treated as follows: 
 Sample A: 10 g/mL plant extract 
 Sample B: 1 g/mL 
 Sample C: 0.1 g/mL 
 Sample D: 0.01 g/mL 
 Sample E: 0.001 g/mL 
 Sample F: Positive Control (IFN-alpha for HCV) 








Table 8 a: Time Scale Treatment Schedule 
Treatment 
Day/Sample 
Day -1 Day 0 Day 4 
Sample A-G Seed the cells Add plant extract 
treatment 
End of treatment 
 
 
Table 8 b: Time Scale Treatment and Plates Schedule 
Treatment 
Day/Plate 
Day 0 Day 1 Day 2 Day 4 







viability and save 
the supernatant 
to extract viral 
RNA.  Viral 
RNA levels will 
be determined by 
real-time PCR 
  






 Measure cell 
viability and save 
the supernatant to 
extract viral RNA.  
Viral RNA levels 
will be determined 
by real-time PCR 
 






  Measure cell 
viability and save 
the supernatant to 
extract viral RNA.  
Viral RNA levels 
will be determined 
by real-time PCR 
 
Four identical plates will be running at the same time with the exact same 
conditions as indicated above.  At Day 0, we will be seeding the cells, which means 
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we will be plating freshly split cells onto cell culture plates.  After 24 hours, when the 
cells have had a chance to adhere to the cell culture plate and grow, treatment can 
begin.  At different points in time, we will "sacrifice" a plate to get a measurement of 
the cell viability and the medium, or supernatant, will be saved and stored in -80°C 
freezer.  That way, we will be able to extract viral RNA from it later and run a real-
time PCR assay to determine viral load concentrations.    
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Appendix M: Anatomy of Phyllanthus Niruri (Krishnamurthy, 2012) 
 
Drawing of the anatomy of Phyllanthus niruri that includes the (a) the branch, (b) 





Amplify: increase the number of copies of a specific gene using PCR 
 
Analytical HPLC: High Pressure Liquid Chromatography. This type of 
chromatography follows the same principles as basic chromatography but allows the 
user far better control over the system. With HPLC you are able to control solvent 
flow, gradient, and specific run time. The columns utilized in this form of 
chromatography also are far more controlled.  
 
C4/C8/C18 HPLC Column: HPLC column are filled with tiny glass beads coated 
with varying sizes of hydrocarbon chains. The length of the carbon chain determines 
the "stickiness of a column". A C4 column would mean that there is are many four 
carbon chains attached to the bead available to interact with what is injected into the 
column. A long carbon chain has a better capability to interact with an hold on longer 
to compounds flowing through the column. The more nonpolar the compound 
flowing through, the even strong the interaction where as a polar molecule will be 
able to flow through with less interactions. To have optimal separation, meaning 
compounds will come out separately from each other, selection of the proper column 
is essential. Since nonpolar molecules will be mostly found in the organic extracts, 
which utilize non polar solvents, you would want to use a column with a short carbon 
chain (C4 or possibly C8) otherwise the column may never eluted the compound. 
(Think about stick two sides of tape together). Where as aqueous extract which would 
contain polar compounds, thus you would want to use a "stickier" column to 
maximize the interactions thus get better separation. 
 
Conventional drug therapy: standardized treatment currently used against HIV and 
HCV; T-20 is a potent synthetic protein that inhibits the replication of HIV-1. 
 Interferon-alpha is a chemokine, or a white blood cell that attracts other immune 
system cells to a site of injury in the body, and is the standard treatment against HCV. 
 This drug is often combined with ribavirin to stabilize the interferon in the body to 
prevent it from degradation by enzymes. 
 
Chromatography: is a method of separating compounds based on physically 
properties, in our case polarity. All chromatography has three major elements. The 
mobile phase is the solvent you flow through the column. The stationary phase part 
that remains stationary in the column. Both of these interact with your the compound. 
The compound will want to flow through the column with the mobile phase, but will 
also interact with the stationary phase to prevent movement. The relative polarities of 
the compound compared to the mobile phase and the stationary phase determine how 
it will move through the column. If there are multiple compounds, each with different 
physical properties they will move through the column with different rates, thus 




DNeasy spin column: a type of microcentrifuge tube with a filter to catch DNA 
 
Flow cytometry: technique for counting, examining, and sorting microscopic 
particles, such as cells and chromosomes.  The particles are suspended in fluid and 
analyzed through electronic detection. 
 
Flow rates: the actual amount of liquid moving through the HPLC column per a unit 
of time 
 
Genetic barcode: due to the evolution of DNA over time, certain genes can be found 
ubiquitously in many living organisms, such as plants.  For a plant genetic barcode, 
the gene must be common enough across all plant species, but distinct enough that the 
sequence of the gene is different in each species.  If a gene fulfills these requirements, 
then the sequence of that gene will be associated with a specific species, and thus be 
used to identify a plant. 
LC/MS Mass spectrometry: Liquid Chromatography/Mass Spectrometer. Molecules 
are separated through HPLC and then aerosol and hit with a beam of high speed 
electrons to cause fractionation. The fractions each have a positive charge in at least 
one place, and pulled across a magnetic field to a detector on the other side. More 
massive particles will be more difficult to move to the detector and will hit lower on 
the detector depended on their mass. the place where their hit the detector, combined 
with their know charge can be used to find the molecular weight of a molecule. 
 
Lyse: break open cells for the purposes of extracting intracellular material, such as 




Lymphocyte: white blood cell of the immune system to help fight off infection or 
disease 
 
Mist room: a room that maintains humidity and soil moisture at appropriate levels in 
a greenhouse using misting apparatuses 
 
Molecular barcode: see genetic barcode 
 
NMR: Nuclear Magnetic Resonance; the effect of a magnetic field on a molecule will 
result in a distinct graph of speaks, which can be used to identify the molecule's 
structure 
 
Partitioned: separation of compounds through their solubility in two immiscible 




Polymerase chain reaction (PCR): a technique to amplify DNA by generating 
thousands of copies of a particular DNA sequence through a repeated cycle of heating 
and cooling. 
 
Primer: a series of nucleotides that catalyze DNA replication. 
 
QIA shredder: type of microcentrifuge tube that is used in the lysis of cells 
 
Reflux: involves letting a reaction boil with a condenser above it. This serves to 
allow the liquid to completely enter the gaseous phases before recondensing and 
dripping back down into the reaction mixture. It is a technique often used in many 
organic chemistry processes. 
 
Retention Time: this is a property of HPLC. Once we have specifically defined the 
parameters for our HPLC separation methods (flow rate, solvent gradient, column 
length and type, run length) the time at which a compound elutes is known as the 
retention time. It is specific to that compound and can be used for identification. 
 
Sequencing: to sequence a fragment of DNA means to find the order of the DNA 
nucleotides (adenosine (A), cytosine (C), thymine (T), and guanine (G))  
 
Soxhlet extraction: an extraction performed by boiling a solvent with the plant 
material and allowing the solvent, along with the soluble compounds, to vaporize and 
recondense into a separate collection flask.  
 
Solvent gradient: this involves change the rate and percentage of solvent flow 
optimal peak shape in HPLC. HPLC utilizes two different solvents denoted by A and 
B. We will have solvent A as water and B as acetonitrile. The solvent in 
chromatography is known as the mobile phase and is what essentially pulls the 
compounds along the beads (known as the stationary phase). Starting with a solvent 
ratio of A 100: B 0 you are able to pull along compounds that are highly polar as it 
will have a stronger interaction with the mobile phase than with the stationary phase. 
Then by changing the solvent ration you can pull along other compounds with 
different polarities. The method through which you change the solvent ratios over 
time is known as the solvent gradient. Different gradients, combined with flow rates 
change how the compounds exit the column and are picked up by the UV detector. 
  
Washing: using solvents and wash detergents to purify genetic material, such as 
RNA or DNA 
 
UV Spectra: a graph of the ultraviolet absorbency of compounds at different 
ultraviolet wavelengths. 
 




Viral load: level of viral genetic material in the cell and serves as an indication for 
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